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1. Introduction 
1.1      Oxidative Stress and Cancer Progression. 
Cancer progression has been viewed as an evolved adaptation of normal 
cells to a sustained cancer stress microenvironment by succeeding matched 
gene mutations and cellular non-genetic alterations.  Cellular adaptive 
consequences result in multiple malignant phenotypes, including self-sufficiency 
in growth signals, insensitivity to anti-growth signals, evading apoptosis, limitless 
replicative potential, sustained angiogenesis and tissue invasion and metastasis, 
which are known as six hallmarks of cancer. 1 In the past decade, another two 
emerging hallmarks have been added to this list, known as reprogramming of 
energy metabolism and evading immune destruction. 2 
Oxidative stress is defined as an imbalance of the pro-oxidant antioxidant 
ratio and is characterized as an increase in reactive species (RS).  RS are the 
essential components of cellular redox system and play multiple roles in human 
physiology and pathology, including two main groups – ROS (derived from 
oxygen, such as superoxide (O2-·), hydrogen peroxide (H2O2), hydroxyl radical 
(·OH)) and RNS (containing nitrogen, such as nitric oxide (NO·) and peroxynitrite 
(-ONOO)). 3 Oxidative stress has been implicated in cancer development through 
modifying cellular structure, gene expression and enzyme function. 4,5 The 
etiological study of cancer has indicated that oxidative DNA lesions are 
correlated with the tumor related gene mutations. 6,7 However, some cancer 
pathological studies also argued that the increase of oxidative DNA lesions, such 
as 8-OH-G, is not sufficient to cause malignancy. 6,7 In non-malignant cells, the 
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elevated level of cellular oxidative DNA lesions may also cause apoptosis or 
cytotoxicity.  In addition, cellular DNA repair process plays an important role for 
maintain genome stability through limiting the elevated oxidative DNA lesions.  A 
previous study indicated that RS could also impair cellular DNA repair machinery 
and result in the accumulation of DNA mutations. 8 Besides the direct genetic 
modification, studies have also demonstrated the crucial role of RS in mediating 
the tumorigenic function of some non-genotoxic carcinogens.9 These findings 
suggested that oxidative stress plays an important role in cancer signal 
transduction.  Further, tumorigenesis studies have demonstrated that RS is 
required to mediate downstream pathway activation of oncogenes and functional 
inactivation of tumor suppressors. 10,11 Because persistent oxidative stress can 
induce various cellular damages, RS also serves as a stress source to trigger cell 
adaptation and select the malignant seeds leading to abnormal cell growth and 
survival. 12 Besides regulating cell survival, RS functions as microenvironment 
stimuli that reprograms cell energy or redox metabolism, and causes Warburg 
effect or the enhanced content of the detoxification factor glutathione (GSH) in 
malignant cells. 13   
1.1.1   Reactive Species Induce Modification of Biological Molecules.  
According to chemical electron status, RS are divided into two groups, 
radical and non-radical species.  Free radical RS refer to those with an unpaired 
electron, which have high free energy and are very reactive.  Superoxide (O2-·), 
hydroxyl radical (·OH) and nitric oxide (NO·) are three main cellular radical RS.  
RS that possess all-paired electrons are called non-radical RS and have a strong 
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oxidizing capacity.  Hydrogen peroxide (H2O2) and peroxynitrite (-ONOO) are two 
main non-radical RS.  Among these RS, O2-· and NO· are two main direct 
byproducts of cell metabolism which are regulated by subsequent cellular redox 
reactions. 14 In general, RS can induce damage, oxidation and nitration on cell 
molecules. 
The oxidative DNA lesions are the most common effects of RS.  Besides 
the direct modification on DNA (8-OH-G), RS also induce nucleotide base 
oxidation and generate pre-mutagenic lesions, such as 8-OH-dGTP and 2-OH-
dATP. 15 These oxidized DNA precursors are incorporated into cell genome DNA 
by DNA polymerase, and further cause cell mutagenesis. 16 This observation was 
also supported by studies in which activation of MTH1 was shown to hydrolyze 
and suppress the accumulation of oxidized nucleotides and decrease the rate of 
tumor formation in aged mice. 17,18  In addition to direct genetic modification, RS 
are also shown to be correlated with DNA methylation, an epigenetic code 
suppressing gene expression.  The increase of DNA methylation is commonly 
coincident with increased pro-oxidants or down-regulation of antioxidants. 19-21  
Furthermore, the impairment of cellular DNA repair system by RS plays a crucial 
role in the development of genome instability.  DNA strand break rejoining and 
base excision repair are the main cellular repair machineries protecting DNA 
against oxidative damage with the reductive environment being important for 
these processes. 8 Elevated cellular RS, such as H2O2, create a pro-oxidant 
intracellular microenvironment, attenuate the cellular DNA repair activity, and 
lead to the accumulation of un-repaired gene mutations. 22  
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Additionally, RS such as ·OH and NO·, also induce post-translational 
modifications on protein products. 23,24  RS-induced reversible modifications, 
such as disulfide bond formation, are largely involved in cell signaling 
transduction; while RS-induced irreversible modifications, such as carbonylation, 
are mainly viewed as the oxidative stress-induced protein damage or cellular 
oxidative stress sensors. 24,25 There are several groups of amino acid residues 
that have been reported mutated or modified by RS in tumor cells, including 
sulfur-containing amino acids, carbonylation targeting amino acids and the 
phosphorylation site residues of proteins. 26,27 Cysteine is a common RS-
sensitive sulfur-containing amino acid, which derives multiple oxidative stress-
generated products.  Mild and moderate oxidative stress result in the reversible 
cysteine modification, such as S-Nitrosylation, glutathionylation Cys-SH, intra- or 
inter-disulphide bond formation Cys-S-S-Cys, mixed disulphide Cys-S-S-
glutathione and sulfenic acid Cys-SOH. These types of modifications may alter 
protein conformations and reversibly inhibit or activate enzymes, such as p53, 
Ras and Akt.  Excessive oxidative stress promotes irreversible oxidized products 
which permanently change the protein activation, such as sulphinic acid Cys-
SO2H and sulphonic acid Cys-SO3H. In addition, carbonylation is also a common 
irreversible event caused by excessive oxidative stress and leads to damaging 
alterations to protein functions. RS induce direct oxidative carbonyl formation of 
lysine, arginine, proline and threonine.  Lysine, cysteine and histidine can also 
undergo carbonylation through interaction with the lipid and glycation oxidative 
products.  In addition, methionine is another sulfur-containing amino acid, 
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oxidized to methionine sulfoxide by RS.  This reversible modification is important 
for the regulation of calmodulin, which is an essential calcium regulatory protein. 
28
  Furthermore, tyrosine phosphorylation induced by RS is an important process 
that regulates cellular kinase activity and functions in multiple-type tumors and 
leukemia.  Intra-disulfide bond formation in tyrosine kinase protein, such as c-
ABL, interrupts the protein kinase activity through regulation of the stability of 
tyrosine phosphorylation. 29  The nitration of tyrosine, a reversible modification 
caused by RNS (nitrogen containing RS) prevents phosphorylation and 
suppresses protein activation, as evidenced by studies of JNK and PKC. 28  
Furthermore, the irreversible oxidative modification Tyr–Tyr crosslink Di-Tyr 
induced by excessive oxidative stress blocks the phosphorylation-mediated 
regulation at tyrosine.  30 
Cellular lipids are highly diverse, interacting with proteins to form plasma 
membranes mediating cellular signal transduction, and are also sensitive to 
oxidative stress.  The most common RS-mediated lipid modification is lipid 
peroxidation which leads to conformation alteration and oxidative degradation of 
lipids. 31 During lipid peroxidation, lipids transfer electrons or lose allylic 
hydrogens to RS generating fatty acid radicals, lipid peroxides or cycling 
peroxides. This process mainly affects polyunsaturated fatty acids, which contain 
multiple double bonds and act as the reactive hydrogen donors. The entire 
process includes two main steps: initiation and propagation.  Highly reactive RS, 
such as ·OH and –ONOO, can react with lipids and produce unstable primary 
fatty acid radicals.  After initiation, the primary fatty acid radicals react with 
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molecular oxygen and further generate unstable peroxyl-fatty acid radicals.  The 
peroxyl-fatty acid radicals may react with other fatty acids to form new fatty acid 
radicals and lipid peroxides or just cyclic peroxides.  This process is a continuous 
cycle due to the new fatty acid radical formation which subsequently changes the 
cellular lipid conformation. Cellular antioxidants, especially the phospholipid 
hydroperoxide glutathione peroxidase, can scavenge lipid radicals and terminate 
the lipid peroxidation chain reaction.  The deficiency of such cellular antioxidants 
results in an elevated lipid peroxidation or damage of cellular membrane 
structures, and subsequently activates cellular stress-sensitive signaling 
pathway.31  
1.1.2   Reactive Species Function in Tumor Growth Signal Transduction. 
Studies have identified that RS can function as signal transduction factors 
that promote cell growth. 1 Cell mitogenic growth factors, such as PDGF and 
TGFα, can promote mitosis through the activation of receptor kinase pathway, 
notably PDGFR/Ras/MAPK pathway. This pathway has been demonstrated as a 
redox sensitive pathway. 32 RS play a role in activated phosphorylation of 
tyrosine kinase receptor and Ras through protein thiol modification, and further 
stimulate the downstream MAPK pathway activation. 32 In addition, RS induce 
the oxidative inactivation of a specific phosphatase, which inhibits this pathway 
that promotes the dephosphorylation of the kinases. 32  Signal transduction 
mediated by RS has also been reported in a study of tumor-related angiogenesis.  
Angiogenesis, the process of the new blood vessel formation, plays an essential 
role in tumor progression and metastasis. Tumor cell-secreted VEGF stimulates 
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the activation of endothelial cells and promotes angiogenesis.  During this 
process, RS function in up-regulating the VEGF expression and mediate the 
activated of VEGFR downstream pathway. 33 HIF-1 is the important transcription 
factor to up-regulate VEGF expression in response to hypoxia. 34  HIF-1 is a 
heterodimer of HIF-1α and HIF-1β.  HIF-1α is localized in the cytosol and 
undergoes an oxygen-mediated degradation process.  RS molecules, such as 
O2-· and H2O2, block such degradation process and stabilize HIF-1α.  The 
stabilized HIF-1α translocates to the nucleus to bind with HIF-1β to trigger the 
transcription activity of HIF-1, and up-regulates VEGF expression as well.  In 
endothelial cells, VEGFR2 is the crucial VEGF receptor to mediate tumor cell-
stimulated tube formation.  RS, especially O2-· derived from cellular NADPH 
oxidase, inhibit the tumor suppressor protein tyrosine phosphatases PTEN, and 
stimulate the auto-phosphorylation-mediated activation of VEGFR2. 33  Besides 
angiogenesis, RS is also involved in regulating integrins during metastasis.  
Integrins are a group of cell surface transmembrane heterodimeric receptor 
proteins, consisting of two non-covalently bound glycoprotein α and β. RS 
promote integrin expression and further stimulate the communication between 
tumor cells and extracellular matrix.35  The ligand binding affinity of integrins is 
regulated by the disulfide formation between α and β glycoproteins, which is a 
redox-sensitive process and depends on the levels of RS. 35 In addition, a late 
stage of tumorigenesis is linked to extra-cellular matrix degradation, which is an 
essential process for endothelial cells migration into the tumor tissue. Matrix 
metalloproteinase (MMP) cooperates with integrins regulating cell invasion and 
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metastasis. 5 MMPs are secreted from tumor cells and phagocytes (especially 
macrophages). 36 RS and RS-sensitive growth factors are also involved in 
regulating MMP expression.  A study has shown that RS promote cellular MMP9 
expression.  Also, VEGF can up-regulate MMP1 and MMP2.  37,38   
Besides the function in promoting cell growth, RS also function as a stress 
source to promote cellular redox-sensitive survival machinery activation, such as 
activating cell survival transcription factors, stimulating kinase pathways and 
altering cellular metabolism. 28 Moderate levels of RS promote cell survival 
through activation of transcription factors, such as NFκB, Nrf2 and HIF-1, as well 
as kinase pathways, such as PI3K/Akt pathway. 28 NFκB mainly responds to 
mitochondria derived RS, and up-regulates anti-apoptotic factors and survival 
antioxidants, such as IAPs and SOD2. 28  Nrf2 mainly responds to the ER stress 
and exogenous carcinogens, and promotes the expression of the acute stress-
induced antioxidants and cellular detoxification factors, such as HO-1 and 
glutathione (GSH) system factors. 28 HIF-1 mainly responds to the cellular 
oxygen status, such as hypoxia, and stimulates the expression of angiogenesis 
factors and energy-generating enzymes, such as VEGF and glycolysis pathway 
enzymes. 28 Besides the above transcription factors, PI3K/Akt kinase pathway is 
another crucial survival pathway involved in the cellular oxidative stress 
response.  The survival function of PI3K/Akt pathway is mainly through up-
regulation of BCL-2 family anti-apoptotic factors, and inactive phosphorylation of 
cellular pro-apoptotic factors or cell death signal mediators, such as BAD and 
ASK1.  28   
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1.1.3   Reactive Species Disrupt Cell Cycle and Evades Cell Death. 
In normal cells, multiple anti-growth signals maintain the cellular quiescent 
status and regulate the homeostasis process that responds to the external or 
intrinsic stress stimuli.   Tumorigenic stress may also force the benign cells into 
cell cycle arrest or apoptosis.  Malignant cells are believed to derive from the pre-
malignant ones which successfully disrupt the normal cell cycle regulation and 
escape from the stress-induced cell death. 1 RS are linked to this process and 
serve as the stress source to promote malignancy transformation.   
At the molecular level, pRb and p53 play important roles in regulating cell 
cycle and function as tumor suppressors.  Disruption of pRb or p53 is a key step 
for tumor progression.  Mammalian pRb and its relatives are the mediators of the 
multiple cell arrest signals.  Hyper-phosphorylation of pRb blocks cell cycle by 
inhibiting the E2F transcription factors which control the expression of genes 
involved in the normal cell cycle, especially from G1 to S stage. 39  The pRb 
pathway cooperates with mitogenic signaling pathways to promote intracellular 
RS generation.  The increased RS activate PKCδ, which promotes the further 
elevation of RS, and forms a RS-PKCδ feedback loop. 40 This RS-PKCδ loop is 
not only involved in inhibition of cell proliferation but also in induction of cell 
survival.  In addition, a previous in vitro study has suggested that pRb is 
regulated by protein oxidation through oxidation of the specific methionine to 
methionine sulfoxide. 41 This modification alters the serine phosphorylation of 
pRb induced by kinases and disrupts the regulating function of pRb in cell cycle.  
Similar to pRb, p53, another crucial factor that regulates cell proliferation, is also 
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regulated by RS, but in a more complicated process.   Responding to the 
different levels of cellular oxdative stress, p53 promotes various biological 
consequences, such as DNA repair, senescence and apoptosis. 5 The 
expression of several crucial antioxidants is regulated by p53 at transcriptional 
level, including GPX1, catalase and SOD2. 42  Additionally, p53 is also involved 
in the regulation of cellular RS generation machineries, such as mitochondrial 
respiratory chain.  Conversely, function of p53 is also regulated by RS-mediated 
protein modification. Protein phosphorylation induces controversy effects on p53 
depending on the RS level.43 There are ten cysteine residues localized in p53 
DNA binding region.  RS could alter the p53 conformation by modifying these 
cysteine residues.  Such structure alterations cause the similar effects of p53 
mutations, and attenuate the p53 DNA binding activity. One study has shown the 
potential malignant biological consequences induced by p53 cycteine residue 
oxidations.  Using an in vivo mouse model, researchers have observed that 
interruption of redox-directed regulation of Cys173, 235 or 239 of p53 caused 
complete loss of p53 tumor suppressor function as well as gained oncogenic 
function. 44 This study showed the potential malignant biological consequences 
induced by p53 cycteine residue oxidations.   
 Taken together, the cellular oxidative stress plays important roles in 
cancer progression through induction of genome instability, interruption of cell 
growth and promotion of cell survival.  RS not only cause DNA mutations that 
activate proto-oncogene or inhibit tumor suppressor, but also mediates malignant 
signal transduction through various biological modifications (Figure 1). 
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Figure 1. Biological functions of oncogene-induced ROS.  The direct effects 
from ROS and the relative biological consequences in malignant 
cells are listed.   
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1.2      BCR-ABL Positive CML and Oxidative Stress.  
Chronic myeloid leukemia (CML) causes abnormal growth and survival of 
myeloid precursor cells in the bone marrow and blood.  CML represents 
approximately 15-20% of all adult leukemia, and often occurs during or after 
middle-age.  CML is grouped into chronic, accelerated and blast crisis phases. 
The chromosome 9/22 translocation (Philadelphia chromosome, Ph) has been 
identified in about 95% CML cases.   Bcr-Abl fusion gene as the result of Ph 
chromosome encodes a tyrosine kinase oncoprotein, which is constitutively 
active and functions distinctly from the endogenous c-ABL. (Figure 2) 45-47 The 
association between CML malignancy progression and BCR-ABL activation has 
been demonstrated in vitro and in vivo. 48-50  There are several variants of BCR-
ABL oncoprotein, including 230 kD, 210 kD and 190 kD isoforms.  The 210 kD 
BCR-ABL (b2a2 or b3a2) is well studied and is linked with the development of 
CML through suppression of normal hematopoiesis and promotion of abnormal 
cell survival in hematopoietic progenitor cells. 51,52 
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Figure 2. The formation of Ph Chromosome and BCR-ABL fusion gene.  
BCR locates on chromosome 22. ABL locates on chromosome 9.  
Chromosome 9/22 translocation generates Ph chromosome and 
BCR-ABL fusion gene.  
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1.2.1   BCR-ABL Induces Cellular ROS Elevation. 
The elevation of cellular oxidants plays an important role in malignancy 
initiation and progression by creating a favorable environment for cancer and 
leukemia cell. 53-57  Superoxide (O2-·) and hydrogen peroxide (H2O2) are the two 
most abundant stable forms of intracellular ROS.  Mitochondria and cellular 
membrane bound NADPH oxidases (NOXs) are key sites for ROS generation in 
leukemia cells.  The accumulation of the intracellular O2-· and H2O2 is mainly 
regulated by superoxide dismutases (SODs) and glutathione peroxidases 
(GPXs). 14  The oxidative environment results in a self-perpetuating process and 
induces tumorigenesis-associated gene mutations by DNA damage.  In addition, 
oxidative stress also induces protein modifications and activates the 
carcinogenesis-related transcription factors or kinases.   
The increased oxidative DNA damage and the elevated intracellular ROS 
production have been observed in BCR-ABL transformed cells, which can be 
abrogated by the treatment of BCR-ABL kinase inhibitor or ROS scavenging 
agents. 58-60 The consistent genetic and redox alterations have been found in 
human CML primary cells compared with normal bone marrow cells from healthy 
donors. 58,59,61 Furthermore, the mechanistic study of BCR-ABL-induced ROS 
elevation has demonstrated that BCR-ABL-induced ROS increase is associated 
with phosphorylation at Tyr-177 residue of BCR-ABL, activation of PI3K pathway, 
up-regulation of cellular glucose metabolism and  elevation of mitochondrial 
respiratory chain activity. 60,62,63  
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1.2.2   ROS and BCR-ABL Activation. 
The kinase activity of BCR-ABL is related with its tyrosine residue 
phosphorylation status, which is negatively regulated by protein tyrosine 
phosphotases (PTPase) through dephosphorylation.  Previous studies have 
demonstrated that H2O2 induces the same effective inhibition of PTPase as 
PTPase inhibitor pervanadate in non-malignancy human megakaryocytic cell 
MO7e.  The inhibition of PTPase by H2O2 can enhance phosphorylation and 
tyrosine kinase activity of proto-oncogene c-ABL. 62 These results have indicated 
that ROS may contribute to the constitutively tyrosine kinase phosphorylation of 
BCR-ABL by suppressing PTPase-mediated protein dephosphorylation.  Besides 
regulating PTPase activity, ROS has been shown to stabilize tyrosine 
phosphorylation of BCR-ABL through generation of protein intra-disulfide bond 
formation. 64  In addition, clinic and laboratory studies have identified that the 
elevated cellular ROS contributes to the generation of tyrosine kinase inhibitor-
resistant mutants by promoting oxidative DNA damage of native BCR-ABL in 
CML cells. 59   
1.2.3   BCL-XL Mediates Cell Death Resistance in BCR-ABL Cells. 
BCR-ABL functions in evading apoptosis and promoting abnormal survival 
in CML cells. 65  B-cell lymphoma-extra large (BCL-XL) is a crucial downstream 
survival factor of BCR-ABL. 66,67 BCL-XL enhances cell survival through 
suppressing the activation of pro-apoptotic factors. 68  In addition, BCL-XL has 
been found to attenuate growth factor withdrawal or CD95 activation-induced cell 
death by preventing the depletion of cellular GSH. 69,70  High intracellular GSH 
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content is the crucial metabolic cofactor for the development of drug-resistance 
and abnormal cell survival. 71-73  One recent study has identified that over-
expression of BCL-XL may cause the dramatic increase of cellular GSH through 
activation of pentose phosphate pathway. 74 A previous study has demonstrated 
that BCR-ABL promotes BCL-2 independent anti-apoptotic function through up-
regulating BCL-XL. 75 Inhibition of BCR-ABL by ABL kinase inhibitor CGP 57148 
(Imatinib) induces severe cell death along with the down-regulation of BCL-XL in 
CML cell line K562.  Over-expression of BCL-XL in parental K562 cells prevents 
CGP 57148-induced cell death. 76 BCR-ABL-induced BCL-XL up-regulation is 
mainly mediated by signal transducer and activator of transcription 5 (STAT5). 77 
The cytokine-independent and kinase-dependent constitutive activation of STAT5 
has been demonstrated in CML cells. 78 Previous studies have identified that 
both SH2 domain and SH3 domain proline-rich binding sites of BCR-ABL are 
required for the activation of STAT5.79  Additionally, hematopoietic cell kinase 
(Hck) interacts with BCR-ABL SH2 and SH3 domains as a downstream activation 
kinase of BCR-ABL. The activation of Hck leads to the phosphorylation of 
STAT5B on Tyr699 residue and stimulates the activation of STAT5. 80 
Intriguingly, two recent studies have indicated that both IL-3R/JAK2 dependent 
and independent regulation play important roles in up-regulating BCL-XL in BCR-
ABL-expressing cells. 81  The elevation of cellular ROS may also be involved in 
mediating up-regulation of BCR-ABL, because previous studies have 
demonstrated that the increase of cellular ROS can mediate the activation of 
STATs in non-BCR-ABL cells, including STAT1, STAT3 and STAT5. 82,83   
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Additionally, BCL-XL repressor, interferon consensus sequence binding protein 
(ICSBP) is also dramatically down-regulated in chronic stage CML patients. 84,85 
Taken together, it is suggested that BCL-XL is a specific BCR-ABL downstream 
survival factor activated through multiple modes of regulation. 
1.2.4   Glutathione Redox Buffer System. 
Glutathione (GSH) is a ubiquitous small thiol peptide at mM range 
concentrations, and functions as the essential intracellular redox buffer factor in 
mammalian cells. 73  Under normal physiological condition, cellular ROS 
scavenging function mainly depends on GSH metabolism.  GSH functions as the 
substrate for the reduction of H2O2 to H2O by GPXs.  GSH oxidized product 
GSSG is recycled back to the reduced form of GSH by glutathione reductase 
(GR). 86  GPX1 is the most abundant intracellular GPX enzyme and plays a key 
role to scavenge H2O2. 87  Therefore, both intracellular GSH content and GPX1 
activity are important for maintaining proper cell redox balance. Cellular GSH 
content is associated with GSH synthesis, transport and distribution.  Two key 
enzymes, γ-Glutamyl-cysteine synthetase (GCLC) and glutathione synthase 
(GSS) catalyze GSH synthesis using glutamate, cysteine and glycine as 
substrates. 88  The intracellular and extracellular GSH transport and distribution 
are regulated by Gluathione-S-transferases (GSTs) and membrane GSH efflux 
pumps. 89     
1.2.5   Clinical Application of BCR-ABL Targeting Inhibitors. 
In the past few years, BCR-ABL targeting inhibitors have been developed 
for the chemotherapy of CML. 90 Imatinib mesylate (Gleevec) has shown high 
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clinical response rate and represents the first generation of BCR-ABL tyrosine 
kinase inhibition reagents.  Due to its good selectivity, Imatinib has become the 
front-line reagent for CML. 91,92 This merit of Imatinib has been demonstrated by 
both a long term randomized clinical study and the successful clinical trial of 
higher dose Imatinib in CML therapy. 93-95  However, only about 65-75% of early 
stage CML patients respond to Imatinib.  Moreover, more advanced stage of 
CML are resistant to Imatinib.  In addition, a set of BCR-ABL mutants have been 
identified to cause Imatinib-refractory CML in patients.  These mutants result in 
the three-dimensional structure alteration at the kinase activation site, and induce 
constitutive kinase activity due to the decrease in Imatinib affinity. 96-99 In order to 
overcome Imatinib-resistance, the second generation BCR-ABL tyrosine kinase 
inhibitors have been developed.  Dasatinib (BMS0354825), one of these second 
generation inhibitors, has been approved for the treatment of CML by the FDA.  
Clinical trials have demonstrated that Dasatinib effectively eliminates various 
Imatinib-resistant mutants except the one harboring BCR-ABL-T315I mutation. 
100-102
 The limitations of BCR-ABL inhibitor reagents have inspired the 
development of alternative therapeutic strategies dependent on the further 
understanding of drug resistance in CML. 103,104 
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2. Hypothesis and Specific Aims 
The major goal of this study is to understand the role of BCR-ABL in 
inducing persistent intracellular oxidative stress in CML.  Oxidative stress occurs 
with an overabundance of ROS, and results in cell differentiation or apoptosis 
under normal physiological conditions.  Previous studies have demonstrated that 
BCR-ABL promotes malignancy development along with the increases of cellular 
and mitochondrial ROS generation.  However, the essential survival factors 
protecting CML cells against oxidative stress are still unclear.  The increase of 
ROS generally triggers the antioxidant response which protects against 
apoptosis through activation of intracellular redox enzymes.  But, are there any 
unique cell survival machineries responsive to oxidative stress in malignant 
cells?  This is a question worthy of further investigation.  Previous studies have 
found that several molecular factors functioning in antioxidant enzyme 
expression are dysfunctional in BCR-ABL cells, such as FOXO3, ATM/ATR and 
P53. 105-107 Consistently, some antioxidant enzymes specifically responsive to 
intracellular H2O2 accumulation are decreased in some BCR-ABL positive 
patients or cultured human CML cells, such as GPX1 and catalase. 92,108 It is 
worth noting that some transcription factors responding to oxidative stress are 
up-regulated or activated in BCR-ABL cells, such as STAT5 and NF-ĸB. 77,109 
Furthermore, their downstream anti-apoptotic factors are over-expressed in BCR-
ABL cells, such as BCL-XL and BCL2. 75,110 These findings suggest that BCR-
ABL may render cells to be more dependent on anti-apoptotic factors rather than 
antioxidant enzymes in tolerating intra- or extra-cellular oxidative stress.  Taken 
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together, I hypothesize that BCR-ABL induces mitochondrial oxidative 
stress, while protecting against oxidative stress-induced CML cell 
apoptosis through up-regulation of BCL-2 family survival factors.  
To address the above hypothesis, I will investigate the following specific 
aims in this study: 
Aim 1: Identifying the function of glucose metabolism in BCR-ABL-
induced mitochondrial oxidative stress.  Previous studies have indicated that 
glucose metabolism is important for mitochondrial ROS increase in cells stably 
transfected with BCR-ABL. 60,62,63 Whether such biological alterations are either 
initial changes induced by BCR-ABL or late adaptations to malignant signals is 
still unknown.   Therefore, the BCR-ABL inducible model will be used to evaluate 
the correlation between glucose metabolism and mitochondrial ROS level. 
Aim 2:  Investigating the role of BCL-2 and BCL-XL in protecting CML cell 
against oxidative stress-induced apoptosis.  Up-regulation of BCL-2 and BCL-XL 
in leukemia has been identified by numerous studies. 75,110 BCL-XL is the direct 
downstream survival factor of BCR-ABL through activation of STAT5.  BCL-2 
functions in malignant development, and mediates BCR-ABL-independent 
Imatinib-resistance in some CML patients. 111 In addition, the heterogeneous 
BCL-XL and BCL-2 has been observed in CML cells.  The goal of this specific 
aim is to identify the dominant survival factors responsive to oxidative stress in 
CML.  To achieve this goal, BCR-ABL inducible cells, CML cells with differentially 
expressing levels of BCL-XL and BCL2, genetically modified BCL-XL or BCL-2 
expressing cells and BCR-ABL stable transformed cells will be used.  The initial 
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survival factor responsive to BCR-ABL induction will be evaluated.  The 
sensitivity of oxidative stress-induced apoptosis and the biological alterations of 
mitochondria will be tested in the cells with differential level of BCL-XL and BCL-
2 expression.  
Aim 3:  Testing the cell killing effects of redox modulating agents in CML.  
BCR-ABL-induced ROS elevation plays an important role in malignancy 
development.  On the other hand, such enhanced ROS accumulation might 
serve as a biochemical basis to preferentially promote cell apoptosis via further 
oxidative stress induction.  BCR-ABL contains multiple redox-sensitive cysteine 
residues which could be oxidized by ROS and cause protein instability.  Previous 
studies have suggested that modulation of cellular antioxidant GSH content by N-
acetylcysteine (NAC, an antioxidant) or BSO (an inhibitor of glutathione 
synthesis) affects BCR-ABL stability. 112,113  Based on the previous findings, I will 
use a redox modulating agent, β-phenylethyl isothiocyanates (PEITC, a natural 
compound found in edible cruciferous vegetables) to target the cellular 
glutathione (GSH) system and test the cell viability of CML cells.   In addition, I 
will also test redox modulation-induced cell killing effects in cells harboring T315I-
BCR-ABL (the most drug-resistant BCR-ABL mutant observed in clinic), T315I-
BCR-ABL transformed cells and T315I-BCR-ABL positive patient samples.   
Furthermore, the effective combination of redox modulating agents and other 
drugs will be also investigated.  CML cells exhibit substantial phenotypic 
heterogeneity.  Certain sub-populations of cells carrying a secondary mutation, 
such as BCL-2, often escape from primary treatment of Imatinib and enhance 
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disease recurrence risk. Even under the condition that Imatinib is efficient to 
inhibit the activation of BCR-ABL, the diseased cells may still survive but become 
more sensitive to extreme stress.  Using a redox modulating agent PEITC as a 
combination agent may promote massive cell death in such cells.  To test this 
point, I have established a cell model with fluorescence-linked heterogeneous 
BCL-XL and BCL-2 expression in CML cells.  Imatinib or oxidative stress-induced 
cell death will be investigated in the cells with different BCL-XL and BCL-2 
genetic background.   
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3. Materials and Methods 
3.1      Chemicals and Reagents.  
Doxycycline, 30% H2O2, β-phenylethyl isothiocyanate (PEITC, C9H9NS), 
N-acetyl cysteine (NAC), and bovine catalase were purchased from Sigma-
Aldrich (St. Louis, MO).  Imatinib mesylate (Gleevec) and ABT737 were 
purchased from Chemie Tek (Indianapolis, IN).  ‘Active caspas-3, caspase 
inhibitors Z-VAD-FMK and Z-DEVD-FMK were obtained from BD Biosciences 
(San Jose, CA).  The proteasome inhibitor MG132 was acquired from EMD 
biosciences (Calbiochem, San Diego, CA).  Drugs were dissolved in DMSO and 
further diluted with culture medium before use.  The final DMSO concentrations 
in the cell culture medium were less than 0.1% (v/v).  Bovine catalase was 
freshly dissolved in culture media and sterilized by passing through 0.2 µm sterile 
syringe filter (Corning, NY) before use.’114 
3.2      Plasmid Transfection. 
Human HA-Bcl-XL plasmid was a gift from Dr. Paul Chiao and Dr. 
Xiangwei Wu (MD Anderson Cancer Center, The University of Texas).  Human 
GFP-Bcl2 plasmid was obtained from Addgene (Cambridge, MA). Tet-on Human 
Bcl-XL shRNA plasmid was purchased from Thermo Scientific-Open Biosystems 
(Huntsville, AL).  All the transfection reagents were purchased from Life 
Technologies-Invitrogen (Carlsbad, CA).  Cells were starved in serum free media 
for 8-12 hours, and then seeded at 1E6 cells/ml in six-well plates.  Plasmid DNA 
2 – 4 µg was diluted by 500 µl Opti-MEM (Invitrogen), and transfected into cells 
using lipofectamine 2K (Invitrogen).  Transfected cells were cultured in serum 
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free media for another 12 – 24 hours, and then diluted into 2E5cells/ml in culture 
media with 10% serum.  2 µg G418 (Cellgro, Manassas, VA) was used in the 
selection for HA-Bcl-XL and GFP-Bcl2 transfected cells. 4 µg Puromycin was 
used in selection for Tet-on Human Bcl-XL shRNA transfected cells.  After one 
month of selection, the enriched HA-Bcl-XL or GFP-Bcl2 transfected cell pools 
were tested for the presence of transgene by Western blotting.  The enriched 
Tet-on Human Bcl-XL shRNA transfected cell pool was maintained in tetracycline 
free media and decrease of BCL-XL in the presence or absence of doxycycline 
0.5 – 1.0 µg/ml was tested by Western blotting. 
3.3      Cell Lines and Cell Culture.  
‘All human and murine BCR-ABL positive cells were maintained in RPMI 
1640 medium with 10% fetal bovine serum (FBS) at 37°C in an atmosphere of 
5% CO2 balanced humidified air.  K562 cell line expressing the 210 kD BCR-ABL 
protein was derived from a female myeloid CML patient in blast crisis. 115 KBM5 
cell line expressing the 210 kD BCR-ABL protein was derived from a female 
myeloid CML patient in blast crisis. 116,117 KBM5-T315I was derived from KBM5 
by exposing to increasing concentrations of Imatinib leading to the selection of 
surviving clones harboring T315I mutation. 118  KBM5-T315I cells were routinely 
maintained in culture medium containing 1 µM Imatinib.  In studies where KBM5-
T315I cells were compared with the parental KBM5 cells, Imatinib was washed 
off and KBM5-T315I cells were cultured in drug free medium for several days 
before the experiments.  All the murine cells are gifts from Dr. Ralph Arlinghaus 
(MD Anderson Cancer Center, The University of Texas).  TonB210 cell line was 
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derived from the murine BaF3 cells by transfection using Tet-on BCR-ABL. 
TonB210 cells were maintained with IL3 at 1.0 – 4.0 ng/ml. The induction of 
BCR-ABL was through addition of 0.5 – 1.0 µg/ml doxycycline into culture media.    
32D-p210 cells were derived from the murine 32D cells by transfection using 
BCR-ABL.  Parental 32D cells were maintained with 1.0 – 4.0 ng/ml IL3.  BaF3-
Bcr-Abl cells and BaF3-Bcr-Abl/T315I cells were derived from the murine BaF3 
cells by transfection using BCR-ABL or T315I-mutated BCR-ABL.  119-121 ‘114 
3.4      Isolation of Primary CML Cells. 
‘Normal lymphocytes and primary CML cells were isolated from fresh 
peripheral blood samples from health donors and CML patients, respectively, 
after obtaining informed consent in accordance with a research protocol 
approved by M. D. Anderson Cancer Center institutional review board (IRB).  
Patients CML1 and CML2 were at blast crisis stage.  Patient CML2 was identified 
to carry BCR-ABL-T315I mutant.  Cells were isolated using gradient 
centrifugation with Fico/Lite lymphoH (d=1.077, Atlanta Biologicals, Atlanta, GA).  
After isolation, cells were washed by phosphate-buffered saline (PBS) and 
suspended in fresh culture medium.  All drug treatments started after the cells 
were pre-cultured for 24 hours.  The peripheral blood specimens were obtained 
from CML patients after proper informed consent under a research protocol 
approved by IRB of the University of Texas MD Anderson Cancer Center.’114 
3.5      Measurement of Cellular ROS. 
‘Cellular ROS contents were measured by incubating the control and 
experimental cells with 1.0 - 2.5 µM of CM-H2DCF-DA (Life technologies-
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Invitrogen, Carlsbad, CA) for 60 minutes as the chemical probe for ROS.   CM-
H2DCF-DA is cell membrane permeable, and once insider cells, reacts with H2O2 
and other ROS species to generate green fluorescence.  The intensity of green 
fluorescence, reflecting cellular ROS contents, was measured by flow cytometric 
analysis. ‘114  
3.6      Measurement of Mitochondrial ROS. 
Mitochondrial ROS contents were measured by incubating the control and 
experimental cells with 1.0 - 2.0 µM of MitoSOX Red (Life technologies-
Invitrogen, Carlsbad, CA) for 60 minutes as the chemical probe for mitochondrial 
ROS.   MitoSOX Red is cell membrane permeable, and accumulates in the 
mitochondria and mainly reacts with superoxide to generate red fluorescence.  
The intensity of red fluorescence, reflecting mitochondrial ROS contents, was 
measured by flow cytometry.  
3.7      Measurement of Cell Lactate Release. 
Cell lactate production during growth was detected by the Accutrend 
Lactate analyzing system purchased from Roche (Mannheim, DE).  Differentially 
treated cells were incubated in fresh media for 48 hours. Each aliquot of the 
cultured media was collected at a volume of 30 µl to detect lactate concentration 
in a range between 0.8 – 22 mM according to manufacturer’s instruction.  
3.8      Oxygen Consumption in Whole Cells. 
Oxygen consumption in cells was measured by a Clark type oxygen 
electrode system purchased from Hansatech Instruments (Norfolk, UK).  Cells 
were incubated with different experimental conditions, and then harvested by 
 29 
centrifugation.   The samples were resuspended in air saturated 37°C media (O2 
21%) and immediately added into the oxygen chamber.  The oxygen 
consumption rate was measured in the sealed off chamber for 15 minutes.  
Oxygen consumption curves were generated for each experimental condition.     
3.9      Measurement of Mitochondrial Membrane Potential. 
Mitochondrial membrane potential was assessed by the cationic voltage-
sensitive lipophilic dye Rhodamine 123 (Life technologies-Invitrogen, Carlsbad, 
CA).  Cells were incubated with different experimental conditions and labeled 
with 200 nM Rhodamine 123 for 30 minutes.  The fluorescence of Rhodamine 
123 in the washed and resuspended samples was measured in channel FL-2 by 
flow cytometry.  The dramatic drop of florescence is indicative of mitochondrial 
membrane collapse.  
3.10 Detection of GFP-BCL2 Mitochondrial Localization. 
MitoTracker Red (CMXRos, Life technologies-Invitrogen, Carlsbad, CA), a 
red fluorescent dye to stain mitochondria in live cells, was used to visualize 
mitochondria.    Mitotracker Red was directly added into cell suspensions at 200 
nM for 60 minutes.  Total 0.5E5 cells of each sample were collected for cytospin.  
The slides and filters were placed into appropriate slots in the cytospin.  Cells 
were loaded into chamber and collected onto slide by spin down at 1000 RPM 10 
minutes (Shandon Cytospin 2).  The samples on slides were washed with cold 
PBS twice and fixed with 4% paraformaldehyde for 20 minutes.  Samples were 
then coated with Mounting Medium with DAPI purchased from UltraCruz (Santa 
Cruz, CA), and further analyzed by confocal microscope. 
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3.11 Isolation of Mitochondria. 
Cell pellets were washed with cold PBS, and then resuspended in RSB 
buffer (10 mM NaCl, 1.5 mM CaCl2, 10 mM Tris-HCl, pH 7.5) to allow cells TO 
swell for 10 minutes.  The pellets were homogenized with a tight-fit glass tissue 
homogenizer for 10 strokes, and the mixed with 2.5 X MS buffer (525 mM 
mannitol, 175 mM sucrose, 12.5 mM Tris-HCl, pH 7.5, 12.5 mM EDTA) to the 
final 1 X MS buffer concentration.  Nuclei and unbroken cells were removed from 
homogenates by centrifugation at 1300 g for 5 minutes twice.  The supernatants 
were transferred to fresh tubes and centrifuged at 17,000 g for 20 minutes to 
pellet mitochondria fragments.  The mitochondria pellets were further washed 
with 1 X MS buffer three times, and then resuspended in SDS lysis buffer for 
Western blotting analysis. 
3.12    Measurement of Cellular Glutathione. 
Two different methods were used to evaluate cellular glutathione. ‘In one 
way, total cellular glutathione contents were measured by using a DTNB-enzyme 
cycling glutathione assay kit (Cayman Chemical, Ann Arbor, MI).  Cell extracts 
were prepared from the control or drug-treated cells by sonication and 
deproteinization.  The glutathione and DTNB reaction product, yellow colored 
TNB, was detected by 96-well plate reader at absorbance A414 nm.  The cellular 
glutathione contents were calculated using the standard curve generated in the 
experiments with parallel standard glutathione samples, and data from each 
individual experiment were normalized to control (100%).’114  In the other way, 
relative cellular glutathione levels were measured by incubating the control and 
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experimental cells with 200 - 400 nM of CMFDA (Life technologies-Invitrogen, 
Carlsbad, CA) for 60 minutes as the chemical probe for cellular thiols.  CMFDA is 
cell membrane permeable, and reacts with thiols to generate green fluorescence.  
The intensity of green fluorescence, mainly reflecting free glutathione contents 
(98%), was measured by flow cytometry.  
3.13    Quantitative Real-Time PCR Analysis for GPX1 Expression. 
32D and 32D-p210 cell pellets were collected at the exponential growth 
stage.  Total RNA of each sample was isolated using TRIzol Reagents 
purchased from Life technologies-Invitrogen (Carlsbad, CA).  The first strand 
cDNA was generated from 1µg total RNA by reverse transcription using 
SuperScript VILO cDNA Synthesis Kit purchased from Life technologies-
Invitrogen (Carlsbad, CA). The mRNA expression file of Gpx1 was assessed by 
real-time PCR analysis using SYBR Green PCR Kit purchased from Life 
technologies-Applied Biosystems (Carlsbad, CA).  The primers used in this assay 
are listed as following: Murine GPX1 forward 5’-CATTGCCTGGAACTTTGAGA-
3’, reverse 5’-CGATGTCGATGGTACGAAAG-3’; Murine ACTB forward 5’-
CTCTTCCAGCCTTCCTTCCT-3’, reverse 5’-TGCTAGGGCTGTGATCTCCT-3’. 
3.14    Immunoblot Analysis. 
‘Protein lysates were prepared from the control and drug-treated cells, 
separated by electrophoresis on 8% to 15% SDS-PAGE, and transferred to 
nitrocellulose membranes. The molecules of interest were detected using specific 
antibodies as described previously.  Primary rabbit polyclonal antibodies against 
full length and cleaved BCR-ABL, caspase-3, BCL-2, BCL-XL, GPX-1, MCL-1, 
 32 
BAX, HSP60, HA, phspho-c-ABL Tyr245 and phospho-FOXO3a Thr32 were 
obtained from Cell Signaling Technology (Boston, MA). Primary mouse 
monoclonal antibody against poly (ADP-ribose) polymerase (PARP) was 
purchased from BD Transduction Laboratories (San Diego, CA).  Mitochondrial 
respiratory chain subunit antibodies were from MitoProfile Total OXPHOS 
Human WB Antibody Cocktail purchased from MitoSciences (Abcam, Eugene, 
OR).  Actin was probed as a loading control.’114 
3.15 Cytotoxicity Assays. 
Three different methods were used to evaluate the cytotoxic effect of 
drugs under various experimental conditions.  ‘Cell viability was determined by 3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay 122.  
Cells were treated with various concentrations of drugs in 96-well plates for 72 
hours, and MTT reagent was added and incubated during the last 4 hours of the 
drug treatment.  After washing off the culture medium, the cell pellets were 
dissolved in 200 µl DMSO and OD 570nm was quantified using a 96-well plate 
reader.  Drug sensitivity was compared using the cell survival curves and the IC50 
values, defined as the drug concentration that induced 50% loss of cell 
viability.’114  Cell death was also determined by flow cytometric analysis after the 
cells were stained with propidium iodide (PI) from BD Biosciences Pharmingen 
(San Diego, CA).  After cells were incubated with various experimental conditions 
as indicated in the figure legends, the samples were stained with PI over night 
and analyzed by flow cytometry.  The red fluorescence generated by intracellular 
PI is indicative of cell DNA content.  The dead cells, presenting a dramatic loss of 
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DNA, are named as sub-G1 population.  The percentage of sub-G1 population in 
the whole sample represents the status of cell death.  Additionally, cell apoptosis 
was determined by flow cytometric analysis after the cells were double-stained 
with Annexin-V-FITC and PI, using an assay kit from BD Biosciences 
Pharmingen (San Diego, CA).  After cells were incubated with various 
experimental conditions as indicated in the figure legends, the samples were 
stained with Annexin-V/PI.  The Annexin-V-FITC only positive cells are pre-
apoptosis cells. The Annexin-V-FITC and PI double positive cells are apoptosis 
cells.  The Annexin-V-FITC and PI double negative cells are viable.   
3.16    Statistical Analysis. 
The flow cytometry results were analyzed by BD FACSCalibur equipped 
with Becton Dickson CellQuest Pro software (San Jose, CA) and FlowJo 
(Ashland OR).  The comparison between the control and experimental samples 
were tested for statistical significance by the two-tailed Student’s t-test.  
Significance was determined at p<0.05 and the 95% confidence interval. Data 
analysis was performed with PRISM 5.0 (GraphPad, San Diego, CA) 
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4. Results 
4.1 BCR-ABL Promotes Mitochondrial Oxidative Stress through 
Enhancement of Glucose Metabolism. 
4.1.1   Over-expression of BCR-ABL is Correlated with Cellular ROS Increase. 
The murine BCR-ABL inducible cell line TonB210 was used to evaluate 
the level of cellular ROS by probing with DCF-DA.  BCR-ABL expression is 
induced by doxycycline ranging between 0.5 and 1.0 µg/ml.  The BCR-ABL non-
induced cells served as control and maintained in tetracycline free media with 
IL3.   I further detected BCR-ABL expression and cellular ROS level at the 
different time points during BCR-ABL induction.  BCR-ABL was detected by 
Western blotting using anti-c-ABL antibody.  The total cellular ROS was indicated 
by the amount of green fluorescence derived from DCF-DA probe.    BCR-ABL 
showed the time-dependent increase during induction at 12, 24 and 36 hour 
points (Figure 3A).  The consistent time-dependent increase of total ROS was 
also observed in the samples with the increase of BCR-ABL expression (Figure 
3B). Based on the above experimental results, this indicates that increase of 
ROS is correlated with BCR-ABL over-expression.   
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Figure 3. Over-expression of BCR-ABL is correlated with cellular ROS 
increase in TonB210 cells.  (A) BCR-ABL was induced by 0.5 µg/ml 
doxycycline in TonB210 cells.  (B)  Intracellular ROS was detected 
by flow cytometry using DCF-DA probe in BCR-ABL over-
expressing cells. 
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4.1.2   Activation of BCR-ABL Causes the Enhancement of Glucose Metabolism. 
TonB210 cells were cultured with or without doxycycline for 48 hours.  The 
doxycycline treated cells were either incubated with 5µM Imatinib or not.   Cells 
were cultured with IL3 in order to prevent cell death in parental cells or Imatinib 
treated BCR-ABL over-expressing cells.  The amount of glycolysis end product 
lactate released from the differentially treated TonB210 cells has been 
measured.  BCR-ABL over-expressing cells showed a significant increase of 
lactate products (Figure 4, Upper).  Furthermore, Imatinib significantly 
suppressed the enhancement of lactate in BCR-ABL over-expressing cells 
(Figure 4, Upper) along with the inhibition of BCR-ABL tyrosine kinase activation 
(Figure 4, Lower).  These results suggested that BCR-ABL onco-protein activity 
is required for the enhancement of cellular glucose metabolism.  In addition, no 
dramatic changes of cell oxygen consumption were observed in BCR-ABL over-
expressing cells (Figure 5). This result excludes mitochondria inhibition as the 
cause of glycolysis activation.  Taken together, the above results have identified 
that the enhancement of glucose metabolism is an early event induced by BCR-
ABL through its kinase activity.    
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Figure 4. Activation of BCR-ABL enhances glucose metabolism in TonB210 
cells. The medium lactate product released from differentially 
treated TonB210 cells was measured.  Lactate amount was 
normalized by cell numbers.  Doxycycline 0.8 µg/ml was used to 
induce BCR-ABL expression for 48 hours.  Imatinib 5µM was used 
to inhibit BCR-ABL tyrosine kinase activity.   Active form and total 
BCR-ABL were detected by Western blotting using phosphor-BCR-
ABL and c-ABL antibody.  All the samples were cultured in the 
presence of IL3. 
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Figure 5. No decrease of oxygen consumption rate in BCR-ABL over-
expressing cells.  Doxycycline 0.5 µg/ml was used to induce BCR-
ABL expression in TonB210 cells.  Oxygen consumption rate was 
detected using 8 million cells for each sample.   BCR-ABL 
expressing cells were collected at 12 and 36 hour. 
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4.1.3  Glucose Shortage Results in Decreased Mitochondrial ROS Generation in 
BCR-ABL Expressing Cells. 
The level of cellular ROS and mitochondrial ROS were measured under 
normal or glucose shortage conditions by probing with DCF-DA and MitoSox 
Red, respectively.   Both cellular and mitochondrial ROS elevations induced by 
BCR-ABL were suppressed under the glucose shortage conditions (Figure 6).  In 
addition, no dramatic cell death was induced by glucose shortage (Figure 7), 
which excludes the interruption of cell survival as the cause of ROS decrease.   
To further prove this point, mitochondrial ROS generation was detected under 
the glucose shortage conditions in human cultured CML cells.  Mitochondrial 
ROS level was measured in two BCR-ABL positive CML cell lines K562 and 
KBM5 using MitoSox Red probe.  After 20 hour glucose shortage culture, 
mitochondrial ROS dramatically dropped in both cell lines (Figure 8).   In addition, 
the effects of glucose shortage on cell survival were tested in K562 cells.  There 
was no dramatic cell death caused by 24 hours of glucose shortage (Figure 9, 
Upper).  Just a slight increase of cell death was induced by 48 hour glucose 
shortage (Figure 9, Lower).  Taken together, my results suggested that 
mitochondrial ROS are highly rely on the glucose nutrient condition, although 
glucose shortage does not promote potent cell death in BCR-ABL expressing 
cells. 
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Figure 6. Glucose shortage decreases BCR-ABL induced cellular and 
mitochondrial ROS increase in TonB210 cells.  Cellular and 
mitochondrial ROS levels were detected by Using flow cytometry 
using DCF-DA and MitoSOX Red probes, respectively.  
Doxycycline 0.8µg/ml was used to induce BCR-ABL expression for 
48 hours.  Cells were cultured with or without glucose supply. 
Sample’s medians are labeled. 
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Figure 7. No dramatic cell death induced by 48 hour glucose shortage in 
TonB210 cells.  DNA content was detected by PI staining assay.  
Doxycycline 0.8 µg/ml was used to induce BCR-ABL expression for 
48 hours.  Cells were cultured with or without glucose supply for 48 
hours. Percentages of sub-G1 population (lethal cell) are labeled. 
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Figure 8. Glucose shortage results in mitochondrial ROS decrease in K562 
and KBM5 cells.  Mitochondrial ROS level was detected by flow 
cytometry using MitoSOX Red.  Cells were cultured with or without 
glucose supply for 20 hours. Sample’s medians are labeled. 
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Figure 9. No dramatic cell death induced by glucose shortage in K562 cells.  
Cell death was detected by Annexin-V/PI assay.  Cells were 
cultured with or without glucose supply for 24 or 48 hours. 
Percentages of survival cells are labeled. 
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4.2 BCR-ABL Downstream Survival Factor BCL-XL Plays an Essential 
Role in Protecting Mitochondria Under Oxidative Stress. 
4.2.1   BCL-XL Protects CML Cells Against Oxidative Stress-Induced Apoptosis. 
BCR-ABL inducible TonB210 cell model was used to test whether either 
BCL-XL or BCL-2 is the primary survival factor during BCR-ABL induction.  
Because TonB210 parental cells were cultured with IL-3, which may promote 
BCL-XL expression, experimental samples were incubated with low levels of IL-3 
at 0.1ng/ml.  More specifically, cells were first incubated with doxycycline in the 
media containing 1.0 – 4.0 ng/ml IL-3.  After 48 hours, the IL-3 level was 
decreased to 0.1ng/ml.  After another 12 hours, control and experimental 
samples were collected.  Expression of BCR-ABL, BCL-2 and BCL-XL were then 
analyzed by Western blotting.  BCL-XL but not BCL-2 was dramatically up-
regulated by over-expression of BCR-ABL (Figure 10).   These results suggested 
that BCL-XL is an initial survival factor promoted by BCR-ABL.   This evidence 
has also implied that BCL-XL may play an important role in response to BCR-
ABL-promoted cellular metabolic alterations, such as oxidative stress.  However, 
both BCL-XL and BCL-2 have been reported to be up-regulated in CML cells.  
Whether BCL-XL is more essential to protect cells against oxidative stress is still 
unclear.  To further test this point, two human cultured CML cell lines, which 
express different levels of BCL-XL and BCL-2 were used to compare cell 
sensitivity to oxidative stress.  CML cell line K562 and KBM5 were both 
established from CML blast crisis patient samples.  K562 showed a relatively 
higher level of BCL-XL but less BCL-2 than KBM5 (Figure 11).    
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Figure 10. Initial up-regulation of BCL-XL by BCR-ABL.  Doxycycline 0.8 µg/ml 
was used to induce BCR-ABL expression in TonB210 for 48 hours, 
followed by a decrease of IL-3 to 0.1 ng/ml in the medium.  Then 
medium IL3 level was decreased to 0.1 ng/ml.  Cell samples were 
collected after additional 12 hour Doxycycline incubation.  Cell 
lysates were analyzed by Western blotting for protein expression 
using c-ABL BCL-XL and BCL-2 antibodies.  Actin was used as a 
loading control.   
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Figure 11. Different expression levels of BCL-XL, BCL-2 and antioxidants in 
K562 and KBM5 cells.  Cell lysates was analyzed by Western 
blotting for protein expression using BCL-XL, BCL-2, MCL-1, GPX-
1 and Catalase antibodies.  Actin was used as a loading control.  
The cell lysate of AML cell line HL60 was used as a control to 
indicate the relative level of BCL-XL, BCL-2, MCL-1 and GPX-1 in 
CML cells. 
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It is worthy of noting that antioxidant enzymes GPX1 and catalase, which 
play major roles in scavenging intracellular ROS products under normal 
physiological conditions, are both expressed at lower levels in K562 than KBM5 
cells (Figure 11).   These results suggested a lower antioxidant capacity in K562.  
To test CML cell sensitivity to oxidative stress, K562 and KBM5 cells were 
incubated with H2O2, a general oxidative stress inducing agent, at 50 µM for 18 
hours.  In addition, cells were also treated with 0.5 µM Imatinib for 60 hours to 
test the cell sensitivity of BCR-ABL inhibition.  Interestingly, H2O2 caused more 
cell death in KBM5 cells, however, Imatinib promoted more cell killing effects in 
K562 cells (Figure 12).  These results indicated that K562 cells are less sensitive 
to oxidative stress than KBM5 cells.   Therefore, BCL-XL which is highly 
expressed in K562 cells seems to play a more dominant role in protecting CML 
cells against oxidative stress than BCL-2.  However, these results were 
generated from the comparison between different cell lines and it is possible that 
other genetic differences between K562 and KBM5 cells may be also involved. 
To further clarify the role of BCL-XL in protecting cells against oxidative stress, 
either BCL-XL expression plasmid or Bcl-XL shRNA plasmid was transfected into 
cultured human CML cell lines.  In this experimental system, I can exclude the 
impacts derived from genetic background of different cell lines.  
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Figure 12. K562 is less sensitive to oxidative stress induced apoptosis than 
KBM5 cells.  Cells were treated with 50 µM H2O2 or 0.5 µM Imatinib 
for 18 or 60 hours respectively. Flow cytometry was used to detect 
cell death by Annexin-V/PI.  Percentages of survival cells are 
labeled. 
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KBM5 cells were transfected with a neo’-containing HA tagged human 
BCL-XL plasmid.  The successfully transfected cells were enriched by selector 
G418 for one month.  The selected cell pool was named as KBM5-BCLXL-HA.  
The over-expressed BCL-XL product was identified by Western blotting using 
BCL-XL and HA antibodies (Figure 13).  KBM5 and KBM5-BCLXL-HA cells were 
incubated with 50 µM H2O2 or 2 µM Imatinib for 24 or 48 hours respectively.  Cell 
death was detected by flow cytometry using Annexin-V-FITC and PI.  The 
increased cell survival of KBM5-BCLXL-HA under treatment of either H2O2 or 
Imatinib was observed (Figure 14).  In addition, I used the same approach to 
generate BCL-XL over-expressing cells from K562, named as K562-BCLXL-HA 
(Figure 15).   K562 and K562-BCLXL-HA cells were treated with 50 µM H2O2 or 2 
µM Imatinib for 60 hours.  Consistent with the results from KBM5 pair cells, the 
increased cell survival of K562-BCLXL-HA under treatment of either H2O2 or 
Imatinib was also observed (Figure 16).   These results have shown that over-
expression of BCL-XL in CML cells reduces cell sensitivity to both oxidative 
stress and Imatinib. Besides these gain of function tests, I further investigated 
BCL-XL loss of function effects in K562 cells.  K562 cells were transfected with 
RFP linked tet-on inducible Bcl-XL shRNA plasmids.  The successful transfected 
cells were enriched by selector 4 µg/ml puromycin for one month, named as 
K562-BCLXL-KD.  After 4 day doxycycline induced shRNA expression, the BCL-
XL level was decreased about 70% (Figure 17).  After induction of BCL-XL knock 
down, cells were treated with 50 µM H2O2 for 24 hours.  Apoptotic cells were 
further detected by flow cytometry using Annexin-V-FITC staining assay.  The 
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pre-apoptotic and apoptotic cells indicated as annexin positive were dramatically 
increased in BCL-XL knocked down cells (Figure 18).    Taken together, these 
results have demonstrated that BCL-XL play an important role in protecting CML 
cells against oxidative stress. 
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Figure 13. Over-expression of BCL-XL in KBM5 cells.  KBM5 cells were 
transfected with HA tagged human BCL-XL plasmids.  The 
successful transfected cells were enriched by selector G418 for one 
month, named as KBM5-BCLXL-HA.  The over-expressed product 
was identified by BCL-XL and HA antibodies. The HA tagged BCL-
XL protein showed a higher molecular weight than the endogenous 
one.  Actin was used as a loading control. 
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Figure 14. Over-expression of BCL-XL enhances cell survival under oxidative 
stress and Imatinib treatment in KBM5 cells.  KBM5 and KBM5-
BCLXL-HA cells were treated with 50 µM H2O2 or 2 µM Imatinib for 
24 or 48 hours respectively.  Cell viability was detected by Annexin-
V/PI assay.  Percentages of survival cells are labeled. 
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Figure 15. Over-expression of BCL-XL in K562 cells.  K562 cells were 
transfected with HA tagged human BCL-XL plasmids.  The 
successfully transfected cells were enriched by selector G418 for 
one month, named as K562-BCLXL-HA.  The over-expressed 
product was identified by BCL-XL and HA antibodies. Actin was 
used as a loading control. 
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Figure 16. Over-expression of BCL-XL enhances cell survival under oxidative 
stress and Imatinib treatment in K562 cells.  K562 and K562-
BCLXL-HA cells were treated with 50 µM H2O2 or 2 µM Imatinib for 
60 hours.  Cell viability was detected by Annexin-V/PI assay.  
Percentages of survival cells are labeled. 
 
 
 
 
 
 
 
 
 
 
 
 68 
 
 
 
 
K562
Control H2O2 50µM 60h
91% 29%
68%85%
10 0
10 1
10 2
10 3
10 4
10 0
10 1
10 2
10 3
10 4
10 0
10 1
10 2
10 3
10 4
10 0
10 1
10 2
10 3
10 4
100101102103104 100101102103104
K562-BCLXL-HA
100101102103104 100101102103104
Annexin-V
PI
Imatinib 2µM 60h
10 0
10 1
10 2
10 3
10 4
100101102103104
29%
10 0
10 1
10 2
10 3
10 4
100101102103104
78%
 
 
 
 
 
 
 
 
 
 69 
 
 
 
 
 
 
Figure 17. Knock-down of BCL-XL in K562 cells.  K562 cells were transfected 
with RFP linked tet-on inducible Bcl-XL shRNA plasmids.  The 
successful transfected cells were enriched by selector puromycin 
for one month, named as K562-BCLXL-KD.  The BCL-XL level was 
identified by Western blotting using BCL-XL antibody after 4 day 
shRNA induction by doxycycline treatment.  Actin was used as a 
loading control. 
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Figure 18. Down-regulation of BCL-XL enhances oxidative stress induced 
apoptosis in K562 cells.  Doxycycline-Induced and non-induced 
BCLXL knock down cells were treated with 50 µM H2O2 for 24 
hours.  Cell apoptosis was detected by Annexin-V (including pre-
apoptosis and apoptosis cells).   Viable cells are annexin negative, 
while apoptotic cells are annexin positive.  Percentages of gated 
cells are labeled.   
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4.2.2  BCL-XL but not BCL-2 Prevents Oxidative Stress-Induced Mitochondrial 
Membrane Potential Collapse.   
The above results have shown that KBM5 expresses relatively higher 
BCL-2, but is more sensitive to oxidative stress-induced apoptosis than K562 
(Figure 11, 12).  This observation implies that BCL-XL and BCL-2 may be 
functionally distinct in response to the increased mitochondrial ROS in CML cells.  
Both BCL-XL and BCL-2 have mitochondrial localization.  Previous studies have 
shown that both BCL-2 and BCL-XL play important roles in the development of 
CML.  BCL-2 especially causes Imatinib resistance in some BCR-ABL positive 
and BCR-ABL-independent CML cells.  Therefore, identification of the differential 
role of BCL-XL and BCL-2 in response to mitochondrial oxidative stress can help 
us further understand the biological mechanism of CML progression, and even 
provide the rationale for the design of novel therapeutic approaches.   To achieve 
these goals, I generated BCL-2 over-expressing cells by transfecting a GFP-
fused BCL-2 plasmid into K562 which has low endogenous BCL-2 background. 
The successfully transfected cells were enriched by G418 selection, and the cell 
pool was named as K562-BCL2-GFP.  Expression of GFP-BCL-2 fusion protein 
was identified by Western blotting using BCL-2 antibody (Figure 19A).  
Mitochondria localization of GFP-BCL-2 fusion protein was identified by confocal 
microscope using MitoTracker Red to indicate mitochondria.  The co-localization 
of GFP and MitoTracker Red showed that a large amount of the over-expressed 
BCL-2 products were successfully localized to mitochondria (Figure 19B).    
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Figure 19. Over-expression of BCL-2 in K562 cells.  K562 cells were 
transfected with GFP-fused BCL-2 plasmids.  The successfully 
transfected cells were enriched by selector G418 for one month, 
named as K562-BCL2-GFP.  (A) The over-expressed product was 
identified by BCL-2 antibodies.  The GFP fusion BCL-2 protein 
showed at a higher molecular weight than the endogenous one. 
Both K562 and K562-BCLXL-HA were used as negative controls.  
Actin was used as a loading control.  (B) The mitochondria 
localization of this GFP-BCL-2 fusion protein was identified by 
confocal microscope (40X) using MitoTracker Red and DAPI 
indicating mitochondria and nuclei respectively.  Cells that showed 
the co-localization of GFP-BCL-2 (green) and mitochondria (red) 
are indicated by arrows. 
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I further detected cell viability of BCL-XL or BCL-2 over-expressing K562 
cells under treatment of H2O2 or Imatinib by PI staining assay. The sub-G1 
population of each sample indicates the dead cells with decreased DNA 
contents.  After 48 hour treatment, both K562-BCLXL-HA and K562-BCL2-GFP 
cells showed protection effects against H2O2 and Imatinib (Figure 20 Upper).  
After 72 hour treatment, however, only over-expression of BCLXL protected cells 
against oxidative stress. In contrast, both over-expression of BCLXL and BCL2 
still effectively prevented Imatinib-induced cell death following a 72 hour 
treatment (Figure 20 Lower).  These results have suggested that BCL-2 is 
equally effective as BCL-XL in protecting cells against inhibitors of BCR-ABL, but 
is less efficient in preventing oxidative stress induced apoptosis than BCL-XL. 
This observation is consistent with the results I found in the comparison between 
KBM5 and K562 (Figure 12).  It is suggested that BCL-XL is more efficient to 
protect cells against oxidative stress than BCL-2, and BCL-2 is more likely to 
delay oxidative stress induced apoptosis in CML cells.  To further address the 
differential role of BCL-XL and BCL2, I tested the effects of the elevated oxidative 
stress on mitochondrial membrane potential in CML cells.  Following the 
treatment of 100 µM H2O2, cell viability and mitochondrial membrane potential of 
CML cells were detected by Annexin-V/PI and Rhodamine 123 staining assays 
respectively.   The total cell count including pre-apoptotic and apoptotic cells was 
matched with the total cell count of cells with collapsed mitochondrial membrane 
potential (Figure 21).   These data indicated that the collapse of mitochondrial 
membrane potential is an early event and contributes to cell apoptosis.   I further 
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compared oxidative stress induced mitochondrial membrane potential changes 
between the BCL-XL and BCL-2 differentially expressing cells.  K562 was found 
less sensitive to 50 µM H2O2 induced mitochondrial membrane potential collapse 
than KBM5 (Figure 22).  Consistently, BCL-XL but not BCL-2 over-expressing 
cells prevented 50 µM H2O2 induced mitochondrial membrane potential collapses 
(Figure 23).  Taken together, these results have suggested that BCL-XL and 
BCL-2 differentially protect cells against oxidative stress, and BCL-XL is more 
efficient in maintaining mitochondrial membrane potential and preventing 
apoptosis than BCL-2. 
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Figure 20. BCL-XL is more efficient in protecting cells against oxidative stress 
than BCL-2.  K562, K562-BCLXL-HA and K562-BCL2-GFP cells 
were treated with 50 µM H2O2 or 2 µM Imatinib.  Cell death and cell 
cycle were detected by PI DNA content staining assay following 48 
hour treatment (Upper) and 72 hour treatment (Lower).  The DNA 
content low sub-G1 population represents the dead cells.   
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Figure 21. Moderate oxidative stress promotes mitochondrial membrane 
potential (MMP) collapse and contributes to cell apoptosis in CML 
cells.  K562 cells were treated with 100 µM H2O2 for 24 hours.  
MMP and cell death were detected by Rhodamine 123 and 
Annexin-V/PI respectively.  Decreased Rhodamine 123 
fluorescence indicates the MMP collapsed cells.  Percentages of 
MMP collapsed and maintained cells are labeled.  Percentages of 
survival (Lower left), pre-apoptosis (Lower right) and apoptosis 
(Upper right) are labeled. 
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Figure 22. K562 is less sensitive to oxidative stress-induced mitochondrial 
membrane potential (MMP) collapse than KBM5.  K562 and KBM5 
cells were treated with 50 µM H2O2 at different time points.  MMP 
was detected by Rhodamine 123.  Decreased Rhodamine 123 
fluorescence indicates the MMP collapsed cells.  Percentages of 
MMP collapsed cells are labeled.   
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Figure 23. Over-expression of BCL-XL but not BCL-2 prevents oxidative stress 
induced mitochondrial membrane potential (MMP) collapse.  K562, 
K562-BCLXL-HA and K562-BCL2-GFP cells were treated with 50 
µM H2O2 for 72 hours.  MMP was detected by Rhodamine 123.  
Decreased Rhodamine 123 fluorescence indicates the MMP 
collapsed cells.  Sample contains MMP collapsed cells shown in 
the divided peak pattern.  The peaks are indicated by arrows. 
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4.2.3 BCL-XL but not BCL-2 Maintains Cell Mitochondrial Integrity Under 
Oxidative Stress.   
The above results suggested that BCL-XL specifically protects 
mitochondria against oxidative stress.  However, whether BCL-XL protects 
mitochondria by limiting mitochondrial ROS generation or enhancing cell 
tolerance of oxidative stress was not answered.  Therefore, I further tested the 
intracellular and mitochondria ROS generation caused by the treatment of H2O2.   
No dramatic difference was observed between BCL-XL over-expressing cells and 
the parental cells (Figure 24).  This result indicated that H2O2 is effective in 
promoting mitochondrial oxidative stress in both cells and BCL-XL mediated 
protection effects on mitochondria is not through limiting mitochondrial ROS 
generation.  Furthermore, I tested the mitochondrial integrity under oxidative 
stress.  Mitochondrial respiratory complexes are the major functional components 
and are localized on the mitochondria membrane space.   The stability of these 
proteins can indicate the function and integrity of mitochondrial organelles.  I 
treated K562, k562-BCLXL-HA and K562-BCL2-GFP with H2O2 for 48 and 96 
hours.  Cell lysates were collected and blotted with different mitochondrial 
complex marker subunits.  A dramatic loss of mitochondrial complex II 30KD 
subunit was observed in K562 and K562-BCL2-GFP but not in K562-BCLXL-HA 
(Figure 25).  Along with this change, endogenous BCL-XL was also found 
decreased in K562 and K562-BCL2-GFP but not in K562-BCLXL-HA (Figure 25).  
These results indicated that BCL-XL plays an important role to maintain the 
stability of mitochondria and mitochondrial membrane bound complexes under 
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oxidative stress.  Additionally, I also blotted these samples with PARP and 
Capase3 antibodies to evaluate the apoptosis activation.  Interestingly, the 
cleavage of Caspase3 and PARP was only observed in K562 (Figure 25).  
However, the decrease of PARP was found in K562-BCL2-GFP, but no cleaved 
Caspase3 was detected (Figure 25).  More important, there was no oxidative 
stress-induced cleavage of either PARP or Capase3 in K562-BCLXL-HA (Figure 
25).  These results have demonstrated that BCL-XL functions in both protecting 
mitochondria and preventing apoptotic activation against oxidative stress. On the 
other hand, BCL-2 can not protect mitochondria against oxidative stress but still 
plays a role in inhibiting apoptotic activation. 
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Figure 24. Over-expression of BCL-XL can not prevent oxidative stress 
induced mitochondrial ROS increase.  K562 and K562-BCLXL-HA 
cells were treated with 50 µM H2O2 for 2 hours.  Cellular and 
mitochondrial ROS levels were detected by DCF-DA and MitoSOX 
Red respectively.  Medians of different samples are labeled. 
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Figure 25. BCL-XL maintains mitochondria integrity and inhibits apoptosis 
activation under oxidative stress.  K562, K562-BCLXL-HA and 
K562-BCL2-GFP cells were treated with 50 µM H2O2 for 48 or 96 
hours.  The cell lysates were blotted with antibodies of 
mitochondrial respiratory complex specific subunits, BCL-2, BCL-
XL, HA, PARP and Caspase3.  Actin was used as a loading control. 
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4.3    Redox Modulation Reagent PEITC Induces Potent Cell Killing Effects 
in Imatinib-Resistant CML cells. 
The figures and texts in this section have been cited and revised from 
‘Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural 
compound PEITC through redox-mediated mechanism. Leukemia. 2008 
Jun;22(6):1191-9.’ 114 
4.3.1  PEITC Increases Cellular ROS and Depletes Cellular GSH in Imatinib-
Resistant Cells.  
‘Imatinib mesylate (Gleevec) is a BCR-ABL tyrosine kinase inhibitor that is 
very effective in the clinical treatment of CML.  However, a set of BCR-ABL 
mutants, especially the T315I mutation, leads to alteration in the three-dimension 
structure of the enzyme active site and exhibits continuously kinase activity and 
resistance to Imatinib.  Such Bcr-Abl mutations impose new challenges in 
treatment of CML.  Based on the previous observations that the BCR-ABL 
oncogenic signal can promote ROS generation and induce cellular redox 
imbalance, I postulated that such oxidative stress might serve as a biochemical 
basis for preferentially triggering ROS-mediated damage to CML cells by further 
oxidative stress with exogenous ROS-generating agents. My study was design to 
test this hypothesis using β-phenylethyl isothiocyanates (PEITC) as an agent to 
modulate cellular redox status in CML cells.  PEITC has previously been shown 
to effectively disable the cellular glutathione system by inducing depletion of 
cellular glutathione and inhibition of glutathione peroxidase activity, and cause 
the massive ROS accumulation in cancer cells. 123  It should be noted that the 
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plasma PEITC concentrations in the µM range were clinically achievable through 
oral administration. 124’114 
To evaluate the biological basis for my above strategy design, the 
correlation between BCR-ABL induced cellular ROS generation and intracellular 
GSH status was tested.  BCR-ABL inducible cell line TonB210 was used to 
detect the level of cellular ROS and GSH along with the over-expression of BCR-
ABL.  The parellel increase of intracellular GSH and cellular ROS upon BCR-ABL 
induction (Figure 26) was observed.  This data suggested that the cellular GSH is 
likely served as cellular defense component responsive to BCR-ABL-promoted 
ROS elevation.  Based on this suggestion, the biological effects of PEITC on 
Imatinib-resistant CML cells were further investigated.  ‘KBM5-T315I cells were 
significantly less sensitive to Imatinib (IC50 = 5.4 ± 0.07 µM) than the parental 
KBM5 cells (IC50 = 0.28 ± 0.05 µM, p<0.0001), and approximate 30% of KBM5-
T325I cells remained viable after treatment with even 10 µM of Imatinib (Figure 
27).  In agreement with my previous prediction, the incubation of KBM5 and 
KBM5-T315I cells with PEITC led to a significant increase in cellular ROS.   
KBM5 and KBM5-T315I cells treated with 10 µM of PEITC for 90 minutes 
showed the dramatic increase of cellular ROS by 129% and 282%, respectively 
(Figure 28).  Additionally, I also confirmed the GSH depletion caused by PEITC 
in both KBM5 and KBM5-T315I cells.  Incubation of cells with 10 µM PEITC 
caused about 30-40% depletion of glutathione at 5 hour, and a complete 
depletion at 10 hour in both KBM5 and KBM5-T315I cells (Figure 29).  Because 
N-acetylcysteine (NAC) is a precursor for glutathione synthesis, pre-incubation of 
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cells with NAC would protect cellular GSH pool.  I found that pre-incubation with 
2 mM NAC largely restored cellular glutathione, even with 10 hour PEITC 
treatment (Figure 29).  This result has suggested that NAC can be used as 
negative regulator of PEITC in my experimental system.’ 114 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 95 
 
 
 
 
 
 
 
 
Figure 26. Over-expression of BCR-ABL elevates cellular GSH along with 
increased ROS.  Doxycycline 0.5 µg/ml was used to induce BCR-
ABL expression in TonB210 cells.  Flow cytometry was used to 
detect cellular GSH and ROS level by CMFDA and DCF-DA, 
respectively. 
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Figure 27. KBM5-T315I cells are resistant to Imatinib-induced cell growth 
inhibition.  KBM5 and KBM5-T315I cells are cultured with Imatinib 
at 0, 1, 3, 6, 10 and 30 µM.  Cell growth was analyzed by MTT 
assay. (Cited from Zhang H. et al. 2008 Leukemia) 114 
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Figure 28. PEITC promotes ROS generation in both KBM5 and KBM5-T315I 
cells.  KBM5 and KBM5-T315I cells are cultured with PEITC (10 
µM, 1.5 hours).  Cellular ROS contents were measured by flow 
cytometric analysis after the cells were stained with CM-H2DCF-DA 
fluorescence dye. (Cited from Zhang H. et al. 2008 Leukemia) 114 
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Figure 29. PEITC depletes cellular GSH in both KBM5 and KBM5-T315I cells.  
KBM5 (A) and KBM5-T315I (B) cells were incubated with 10 µM 
PEITC in the presence or absence of 2 mM NAC for 5 or 10 hours 
as indicated.  Total cellular glutathione contents were then 
measured by using DTNB-enzyme cycling glutathione assay kit.  
(**): The GSH is undetectable in the sample. (Cited from Zhang H. 
et al. 2008 Leukemia) 114 
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4.3.2   PEITC Effectively Promotes Apoptosis in Cells Expressing T315I-BCR-
ABL Mutant Protein. 
‘Based on the hypothesis that the increase of ROS generation in CML 
under the stimulation of BCR-ABL oncogenic signal might render these cells 
highly dependent on glutathione to maintain redox balance, depletion of 
glutathione by PEITC would cause severe ROS accumulation and trigger cell 
death.  Since T315I mutation retains the constitutive tyrosine kinase activity, CML 
cells with this mutation should, like their parental, exhibit increased ROS stress 
and sensitive to PEITC.   
In contrast to the results from Imatinib treatment (Figure 27), both KBM5 
and KBM5-T315I cells were equally sensitive to PEITC, with the IC50 values of 
3.1 ± 0.08 for KBM5 cells and 2.8 ± 0.42 for KBM5-T315I cells (Figure 30A).  
Especially, at 10 µM, PEITC caused complete inhibition of cell growth in both 
KBM5 and KBM5-T315I cells (Figure 30A).  The potent activity of PEITC in killing 
both KBM5 and KBM5-T315I cells was further demonstrated by annexin-V/PI 
assay.  Exposure of CML cells to 10 µM PEITC for 24 hours resulted in 66% and 
63% acute cell death in KBM5 and KBM5-T315I cells, respectively (Figure 30B).  
This result was further confirmed in a pair of murine cell lines derived from BaF3 
by stably transfecting with either the wild-type or T315I mutant Bcr-Abl.  As 
expected, PEITC was also effective in inducing apoptosis in both murine cell 
lines, whereas Imatinib caused cell death only in BaF3-BCR-ABL cells but not in 
BaF3-BCR-ABL-T315I cells (Figure 31).  I further tested the ability of PEITC in 
killing primary CML cells isolated from patients who were clinically resistant to 
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Imatinib treatment.  The primary CML cells from two Imatinib-resistant blast crisis 
patients also exhibited resistance to Imatinib in vitro.  The CML cells from a 
patient with T315I mutation were particularly resistant to Imatinib, with the IC50 
value more than 50 µM (Figure 32A).   In contrast, the CML cells from both 
patients were equally sensitive to PEITC in vitro, with the IC50 values of 8.3 and 
10.5 µM, respectively (Figure 32B).  Consistently, flow cytometry analysis 
revealed that incubation with 10 µM PEITC for 24 hours caused more than 50% 
cell death in the primary CML cells of both patient samples (Figure 32C).  MTT 
assay of a total of 6 CML patient samples showed that the IC50 values of PEITC 
were 13.6 ± 4.04 µM (Table 1).  In contrast to the potent cytotoxicity in primary 
CML cells, PEITC exhibited relatively low cytotoxic effects on normal 
lymphocytes isolated from healthy donors.  Figure 33 shows the dose-response 
curves of two representative normal lymphocytes samples.  The mean IC50 value 
of PEITC in normal lymphocytes was 31.5 ± 5.3 µM, which was significantly 
higher than that of the primary CML cells (P=0.002).  In summary, the above 
results has identified that PEITC is effective in killing CML cells harboring T315I 
mutation, which confers resistance to tyrosine kinase inhibitor Imatinib. ‘ 114 
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Figure 30. Both KBM5 and KBM5-T315I cells are sensitive to PEITC-induced 
growth inhibition and cell death.  (A)  KBM5 and KBM5-T315I cells 
are cultured with PEITC at 0, 1, 3, 6, 10 and 30 µM.  Cell growth 
was analyzed by MTT assay.  (B)  Time-dependent induction of cell 
death by PEITC in KBM5 and KBM5-T315I cells.  Cell death was 
detected by annexin-V/PI assay.  The number shown below each 
panel indicates the percentage of annexin-V and PI double-
negative cells (viable).  (Cited from Zhang H. et al. 2008 Leukemia) 
114
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Figure 31. PEITC induces cell death in BCR-ABL-T315I transformed cells.  
BaF3-BCR-ABL and BaF3-BCR-ABL-T315I cells were incubated 
with 10 µM PEITC or 2 µM Imatinib for 24 h, and cell death was 
measured by the annexin-V/PI assay.  The number shown below 
each panel indicates the percentage of the annexin-V and PI 
double-negative cells (viable). (Cited from Zhang H. et al. 2008 
Leukemia) 114 
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Figure 32. PEITC induces growth inhibition and cell death in Imatinib-resistant 
CML patient samples.  (A, B) Representative dose-dependent 
cytotoxic effect of Imatinib (A) and PEITC (B) in primary CML cells 
with or without T315I mutation.  Cells were incubated with the 
indicated concentrations of Imatinib or PEITC for 72 hours, and cell 
viability was measured by MTT assay.  (C) Induction of cell death 
by PEITC (10 µM, 24 hours) in primary blast crisis CML cells with or 
without T315I mutation.  Cell viability was measured by annexin-
V/PI assay.  The number shown below each panel indicates the 
percentage of viable cells.  (Cited from Zhang H. et al. 2008 
Leukemia) 114 
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Table 1. IC50 values of PEITC in primary Imatinib-resistant CML cells.  The 
primary Imatinib-resistant CML cells were isolated from 6 patients 
clinically refractory to Imatinib.  Cells were incubated with the 
gradient concentrations of Imatinib for 72 hours, and cell viability 
and the IC50 values were measured by MTT assay.  (Cited from 
Zhang H. et al. 2008 Leukemia) 114 
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Sample# CML stage IC50 ±SD (µM)
1 Blast crisis 8.3 ± 0.8
2 Blast crisis (T315I) 10.5 ± 0.8
3 Accelerated phase 10.9 ± 1.5
4 Accelerated phase 13.2 ± 0.9
5 Accelerated phase 16.1 ± 1.6
6 Accelerated phase 16.6 ± 1.0
Mean±SD 12.6 ± 3.3
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Figure 33. Normal donors are less sensitive to PEITC-induced cell growth 
inhibition.  Cells isolated from normal donors were incubated with 
the indicated concentrations of PEITC for 72 hours, and cell viability 
was measured by MTT assay.   
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4.3.3   PEITC Induces BCR-ABL Cleavage and Degradation. 
‘Furthermore, since many proteins, include BCR-ABL, contain redox-
sensitive cysteine residuals which can be oxidized by ROS and affect protein 
structure and stability, I speculated that induction of severe ROS stress in CML 
cells might potentially alter the redox status of BCR-ABL and render it vulnerable 
to degradation.   
Based on the observations that PEITC caused a substantial increase in 
cellular ROS, I tested the possibility that PEITC might alter the protein stability of 
wild-type and T315I mutant BCR-ABL.  Exposure of KBM5 and KBM5-T315 cells 
to 10 µM PEITC caused a and time-dependent decrease of the 210 kD BCR-ABL 
protein.  The decrease of total BCR-ABL proteins occurred as early as 4 hour of 
PEITC incubation, with a concurrent appearance of a 52-kD cleavage product 
(Figure 34).  The ability of PEITC to induce degradation of wild-type and mutant 
BCR-ABL proteins was further confirmed in BaF3-BCR-ABL and BaF3-BCR-
ABL-T315I cells, which express the single isoform of BCR-ABL (Figure 35).  
Since caspase-3 activation and the cleavage of poly (ADP-ribose) polymerase 
(PARP) are hallmarks of apoptosis, I analyzed the cleavage of caspase-3 
(activation) and PARP at various time points after cells were treated with PEITC, 
and evaluated the temporal relationship between the protein cleavage, BCR-ABL 
degradation, and apoptosis activation.  It appeared that caspase-3 activation and 
PARP cleavage occurred before BCR-ABL degradation, and that the cleavage of 
all these three proteins proceeded well before cell death (Figure 34, Figure 
30B).’114   
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Figure 34. PEITC induces cleavage of BCR-ABL and BCR-ABL-T315I mutant 
correlated with caspase-3 activation.  PEITC induced time-
dependent cleavage of BCR-ABL, caspase-3 and PARP in KBM5 
and KBM5-T315I cells.  Cells were incubated with 10 µM PEITC for 
the indicated times, and protein cleavage was detected by 
immunoblotting using the respective specific antibodies.   (Cited 
from Zhang H. et al. 2008 Leukemia) 114 
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Figure 35. PEITC induces decreases of BCR-ABL and BCR-ABL-T315I 
mutant in BCR-ABL over-expressing cells.  PEITC treatment 
induces a time-dependent decrease of BCR-ABL levels in BaF3-
BCR-ABL and BaF3-BCR-ABL-T315I cells.  Cells were incubated 
with 10 µM PEITC for the indicated times, and protein cleavage 
was detected by immunoblotting using the respective specific 
antibodies.   (Cited from Zhang H. et al. 2008 Leukemia) 114 
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‘To further test if caspases or proteasome might be involved in mediating 
PEITC-induced BCR-ABL degradation, I used chemical inhibitors of caspases or 
proteasome to evaluate the role of these enzymes.  Pre-treatment of cells with 20 
µM Z-VAD-FMK, a common inhibitor of multi caspases, effectively prevented the 
cleavage of the wild-type and T315I-mutant BCR-ABL protein, as evidenced by 
the preservation of the full-length (210 KD) BCR-ABL and suppression of the 
generation of the 52kD BCR-ABL (Figure 36, lanes 4-6).  Interestingly, the 
proteasome inhibitor MG132 (5 µM) did not prevent the cleavage of BCR-ABL to 
52 KD fragment (Figure 36, lanes 7-9), but only delay the loss of full length 
protein at the early time point (Figure 36, lane 8).  This held true for both the wild-
type and T315I-mutant BCR-ABL.  Thus, it appeared that the PEITC-induced 
cleavage of BCR-ABL into 52-kD fragment was largely mediated by a caspase, 
whereas proteasome might only play a complementary role to accelerate further 
degradation.  This is in agreement with the previous observations that caspase-3 
is a redox-sensitive enzyme 125 and that inhibition of proteasome by MG132 may 
affect caspase activity in a ROS-dependent manner.  Furthermore, I 
demonstrated that Z-VAD-FMK was able to significantly reduce PEITC-induced 
cell death in both KBM5 and KBM5-T315I cells, whereas MG132 exhibited little 
effect in preventing apoptosis (Figure 37), consistent with the important role of 
caspase in mediating degradation of BCR-ABL.  Because Z-VAD-FMK is a 
broad-spectrum caspase inhibitor, these results did not allow the identification of 
the specific caspase responsive for the cleavage of BCR-ABL.  I then tested if Z-
DEVD-FMK, a specific inhibitor of caspase-3, could prevent BCR-ABL cleavage 
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and suppress PEITC-induced cell death.  I identified that inhibition of caspase-3 
by Z-DEVD-FMK exhibited similar preventive effects on BCR-ABL cleavage and 
cell death as the pan-caspase inbitor Z-VAD-FMK (Figure 38, Figure 39).  This 
result suggested that caspase-3 is the key effective protease that mediates 
PEITC-induced degradation of BCR-ABL and apoptosis.  This is in line with the 
previous observations that the normal c-ABL protein is a substrate of capase-3 
and that this protein structural feature is preserved in BCR-ABL chimeric protein. 
126-129
  Taken together, the above results have suggested that the cleavage of 
BCR-ABL might not be the primary event that triggered apoptosis. The previous 
identified biochemical changes induced by PEITC, such as glutathione depletion 
and ROS accumulation, might be the initial factors to cause cell death in CML 
cells.  More likely, the decrease of BCR-ABL may just accelerate the progress of 
capase-3 mediated apoptosis.’ 114 
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Figure 36. Pan caspase inhibitor prevents PEITC-induced cleavage of BCR-
ABL and BCR-ABL-T315I mutant.  KBM5 and KBM5-T315I cells 
were treated with PEITC with or without a 1-hour pre-treatment with 
20 µM Z-VAD-FMK or MG132.  BCR-ABL and BCR-ABL cleavage 
was detected by immunoblotting.   (Cited from Zhang H. et al. 2008 
Leukemia) 114 
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Figure 37. Pan caspase inhibitor prevents PEITC-induced cell death in KBM5 
and KBM5-T315I cells.  KBM5 and KBM5-T315I cells were treated 
with PEITC with or without a 1-hour pre-treatment with 20 µM Z-
VAD-FMK or MG132.  Cell viability was measured by annexin-V/PI 
assay. The number shown below each panel indicates the annexin-
V/PI double-negative cells (viable).    (Cited from Zhang H. et al. 
2008 Leukemia) 114 
  
 
 
 
 
 
 
 
 
 125 
 
 
 
 
 
 
KBM5
KBM5-
T315I
Control PEITC
PEITC +         
Z-VAD-FMK
98% 50% 80%
93% 18% 79%
Annexin-V-FITC
PI
PEITC + 
MG132
51%
18%
 
 
 
 
 
 
 
 
 
 126 
 
 
 
 
 
 
 
 
Figure 38. Caspase-3 inhibitor prevents PEITC-induced cleavage of BCR-ABL 
and BCR-ABL-T315I mutant.  KBM5 and KBM5-T315I cells were 
treated with PEITC with or without a 1-hour pre-treatment with 20 
µM Z-DEVD-FMK.  BCR-ABL and BCR-ABL cleavage was 
detected by immunoblotting.     (Cited from Zhang H. et al. 2008 
Leukemia) 114 
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Figure 39. Caspase-3 inhibitor prevents PEITC-induced cell death in KBM5 
and KBM5-T315I cells.  KBM5 and KBM5-T315I cells were treated 
with PEITC with or without a 1-hour pre-treatment with 20 µM Z-
DEVD-FMK.  Cell viability was measured by annexin-V/PI assay. 
The number shown below each panel indicates the annexin-V/PI 
double-negative cells (viable).    (Cited from Zhang H. et al. 2008 
Leukemia) 114 
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4.3.4   Elevated Intrinsic Oxidative Stress Mediates PEITC Cellular Effects. 
‘To further demonstrate the essential role of oxidative stress in mediating 
PEITC induced cell killing effects in CML cells, I used the antioxidant N-acetyl-
cysteine (NAC) and the H2O2 scavengering enzyme catalase to evaluate the 
importance of ROS induced by PEITC.  Pre-incubation of cells with 2 mM 
antioxidant NAC almost completely suppressed PEITC-induced ROS increase 
(Figure 40A) and prevented cell death (Figure 41) in both KBM5 and KBM5-
T315I cells.  These results have suggested that intracellular ROS elevation might 
play an important role in mediating the cytotoxic effect of PEITC.  Interestingly, 
pre-incubation with catalase at 500 units/ml only partially reduced PEITC-induced 
ROS increase (Figure 40B), and did not decrease cytotoxicity (Figure 41).  
However, the same concentrations of catalase fully prevented cell death induced 
by exogenous H2O2 (Figure 41).  Because catalase is only functional in extra-
cellular space, the difference I observed above has suggested that the oxidative 
stress induced by PEITC is intrinsic, and this intrinsic stress is important to 
promote apoptosis.  Consistent with this observation, Western blotting analysis 
showed that only NAC prevented the PEITC-induced cleavage of BCR-ABL 
(Figure 42, Lane 7-9), whereas catalase did not suppress BCR-ABL degradation 
(Figure 42, Lane 15-16).  These data also suggested that the intracellular redox 
buffer components are important for the stability of BCR-ABL, and the elevated 
intrinsic oxidative stress might render it vulnerable to degradation.’ 114   
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Figure 40. NAC prevents PEITC-elevated ROS in KBM5 and KBM5-T315I 
cells.  Changes in ROS content in KBM5 and KBM5-T315I cells 
were measured following treatment with10 µM PEITC for 1.5 hours 
with and without a 1-hour pre-treatment with 2 mM NAC or 500 
units/ml bovine catalase.  Intracellular ROS was detected by CM-
H2DCF-DA fluorescent dye (control, purple; NAC or catalase, 
green; PEITC, pink; PEITC + NAC or catalase, blue).  (Cited from 
Zhang H. et al. 2008 Leukemia) 114 
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Figure 41. NAC prevents PEITC-induced cell death in KBM5 and KBM5-T315I 
cells.  Cells were treated with 10 µM PEITC for 40 hours with or 
without a 1-hour pre-treatment with 2 mM NAC or 500 units/ml 
bovine catalase.  For comparison, cells were also treated with 100 
µM H2O2 in the presence or absence of 500 units/ml catalase as a 
positive control for catalase activity. Cell death was determined by 
the annexin-V/PI assay.  The number shown below each panel 
indicates the annexin-V and PI double-negative cells (viable).   
(Cited from Zhang H. et al. 2008 Leukemia) 114 
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Figure 42. NAC prevents PEITC-induced BCR-ABL cleavage in KBM5 and 
KBM5-T315I cells.  Time-dependent cleavage of BCR-ABL 
following PEITC treatment with or without a 1-hour pre-treatment 
with 2 mM NAC or 500 units/ml catalase.  BCR-ABL protein 
expression was detected by immunoblotting.  (Cited from Zhang H. 
et al. 2008 Leukemia) 114 
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4.4   Imatinib and ABT737 Enhances the Sensitivity of CML Blast Crisis 
Cells to Oxidative Stress-Induced Apoptosis.  
4.4.1  Establishing K562-Mix, an in vitro Model with Heterogenic Expression of 
BCL-XL and BCL-2. 
the single target drug BCR-ABL inhibitor Imatinib has high selectivity and 
low side effects.  However, CML cells may exhibit uneven response to Imatinib 
resulted from their phenotypic heterogeneity.  Especially, in some cases, Imatinib 
is effective to inhibit BCR-ABL activity in CML cells, but the alternative survival 
pathway promotes CML cell survival. 130 To solve this problem, the therapeutic 
strategy to limit the survival role of alternative pathway should be developed.  It 
would be useful to establish an experimental model with the heterogenic 
expressions of cell survival factors.  In this model, the phenotypic genotype of the 
drug sensitive or resistant population could be identified.  Therefore, the 
experimental model, K562-Mix was established to detect the drug sensitivity of 
CML cells with different BCL-XL and BCL2 expressions.  Besides K562-BCLXL-
KD (Figure 17) and K562-BCL2-GFP (Figure 19), another cell pool K562-BCL2-
GFP-BCLXL-KD was generated by over-expression of BCL-2 and down-
regulation of BCL-XL using GFP fused BCL-2 plasmid and RFP linked tet-on 
inducible Bcl-XL shRNA plasmid.  The BCL-XL and BCL-2 expression levels of 
the different cell pools were detected by Western blotting (Figure 43).  K562-Mix 
was generated as the mixture of K562, K562-BCLXL-KD, K562-BCL2-GFP and 
K562-BCL2-GFP-BCLXL-KD cells.  
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Figure 43. Establishment of K562-Mix.  K562 cells were transfected with GFP-
fused BCL-2 plasmids.  The successful transfected cells were 
enriched by selector G418 for one month, named as K562-BCL2-
GFP.  K562 cells and K562-BCL2-GFP were further transfected 
with RFP-linked tet-on inducible Bcl-XL shRNA plasmids.  The 
successful transfected cells were enriched by selector puromycin 
for one month, named as K562-BCLXL-KD and K562-BCL2-GFP-
BCLXL-KD, respectively.  Expression of GFP-fused BCL-2 was 
identified by BCL-2 antibodies.  The BCL-XL level after 7 day 
shRNA induction was identified by BCL-XL antibody. Actin was 
used as a loading control.  K562-Mix is the mixture of four cell pools 
including K562 parental, K562-BCLXL-KD, K562-BCL2-GFP and 
K562-BCL2-GFP-BCLXL-KD. 
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The different fluorescence patterns of K562-Mix cells were used to 
represent the different BCL-XL and BCL-2 expressions (Table 2).   The 
percentage change of the different fluorescence pattern in viable K562-Mix cells 
indicates the survival rate of K562-Mix cells with different BCL-XL and BCL-2 
expressions.  An increased percentage of a cell pool indicates a higher survival 
rate or the relative growth advantage of this cell pool in K562-Mix.  In contrast, a 
decreased percentage indicates a lower survival rate or the relative growth 
disadvantage.   
In the K562-Mix experimental model, a non-staining method was used to 
demonstrate cell viability.  Because the dying or dead CML cells often show 
smaller cell size due to shrinkage, FSC high was used as the parameter to gate 
the survived cell population by flow cytometry.  The correlation between FSC 
high and cell survival was tested in K562 parental cells by incubation of Imatinib 
or H2O2.  The FSC high cells showed both Annexin-V and PI negative (viable 
cells) in majority (Figure 44).  Based on this test, the FSC high cells of K562-Mix 
were gated after incubation of Imatinib or H2O2 (Figure 45).  The change of 
percentage was evaluated by the fold numbers calculated based on the data 
from 24 hour cultured original seed sample (Figure 46, Table 3).   K562-BCLXL-
KD cells, expressing low BCL-XL and low BCL-2 and shown as only RFP positive 
in the upper left of each panel, were dramatically suppressed by either Imatinib 
or H2O2.  This data suggested that CML cells with both low BCL-XL and BCL-2 
expressions are hyposensitive to both Imatinib and oxidative stress-induced cell 
death.  K562-BCL2-GFP cells, expressing high BCL-XL and high BCL-2 and 
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shown as only GFP positive in the lower right of each panel, are the largest 
survived population followed with the incubation of either Imatinib or H2O2.  
Because I previously identified that over-expression of BCL-2 did not dramatically 
enhance K562 cell survival ratio with the 72 hour treatment of H2O2 (Figure 20), 
the increased percentage of K562-BCL2-GFP may be caused by the relative cell 
growth advantage under oxidative stress. This data indicated that both BCL-XL 
and BCL-2 contributes to form the treatment-resistant sub-population from 
heterogeneous CML cells.    K562-BCL2-GFP-BCLXL-KD cells, expressing low 
BCL-XL and high BCL-2 and shown as GFP RFP double positive in the upper 
right of each panel, have increased percentage followed with the incubation of 
Imatinib, but not H2O2.  This data suggested that oxidative stress may limit the 
development of BCL-2-over-expressed Imatinib-resistant cell population when 
BCL-XL is down-regulated.   K562 cells, expressing high BCL-XL and low BCL-2 
and shown as GFP RFP double negative in the lower left of each panel, are 
dramatically suppressed by Imatinib, but not that striking by H2O2. 
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Table 2. Correlation between BCL-XL and BCL-2 expression pattern and the 
cellular fluorescence in K562-Mix.  K562-Mix is the mixture of four 
cell pools, including K562 parental, K562-BCLXL-KD, K562-BCL2-
GFP and K562-BCL2-GFP-BCLXL-KD.  Cell pool name, BCL-XL 
level, BCL-2 level and fluorescence status of each cell pool are 
indicated. 
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Figure 44. Gating viable and apoptotic cells by FSC in K562.  K562 cells were 
incubated with PEITC or Imatinib.  Cell death of gated FSC High or 
FSC Low cells was measured by the annexin-V/PI assay.  The 
number shown below each panel indicates the percentage of the 
annexin-V and PI double-negative cells (viable). 
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Figure 45. Gating viable cells by FSC in K562-Mix.  K562-Mix cells were 
incubated with 2 µM Imatinib or 50 µM H2O2 for 72 hours. FSC High 
cell population was gated in each sample.  The percentage of gated 
cells is labeled. 
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Figure 46. Differential cell survival of the different cell pools with the treatment 
of Imatinib or H2O2 in K562-Mix.  K562-Mix cells were incubated 
with 2 µM Imatinib or 50 µM H2O2 for 72 hours. FSC High cell 
population was further analyzed according to the expressions of 
GFP and RFP.  The position of each cell pool is representing as 
follows:  K562 (Lower Left, GFP-/RFP-, BCL-XL High/BCL-2 Low), 
K562-BCLXL-KD (Upper Left, GFP-/RFP+, BCL-XL Low/BCL-2 
Low), K562-BCL2-GFP (Lower Right, GFP+/RFP-, BCL-XL 
High/BCL-2 High),  and K562-BCL2-GFP-BCLXL-KD (Upper Right, 
GFP+/RFP+, BCL-XL Low/BCL-2 Low).  The percentage of each 
cell pool in K562-Mix is labeled.  The uneven distribution in the 
control sample is due to the different cell growth of each cell pool in 
K562-Mix.  
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Table 3. Fold changes of the original seeding population under different 
treatments.  From the percentage data in Figure 46, the fold 
changes of the different cell population in K562-Mix were calculated 
between its statistical percentage results from the original seeds 
(Left) and the experimental sample (Right).  The number shown in 
different color indicates increase (Red), no dramatic change (Blue) 
and decrease (Green). 
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0.81 ± 0.051.43 ± 0.130.83 ± 0.08K562-BCL2-GFP-
BCLXL-KD
1.43 ± 0.012.02 ± 0.010.84 ± 0.02K562-BCL2-GFP
0.55 ± 0.070.14 ± 0.031.12 ± 0.04K562-BCLXL-KD
0.79 ± 0.030.32 ± 0.021.17 ± 0.06K562
H2O2-ImatinibControlK562-Mix
Red: > 1.25, increase
Blue: 0.75 - 1.25
Green: < 0.75, decrease
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4.4.2  Imatinib and ABT737 Enhances Oxidative Stress-induced Apoptosis in 
BCR-ABL Cells.   
The results from the above experiments have suggested that CML cells 
with both high BCL-XL and high BCL-2 expression may have higher chance to 
develop into a drug resistant population, and down-regulation or inhibition of 
them would enhance cell drug sensitivity.  Based on these suggestions, I 
postulated that Imatinib may enhance the sensitivity of oxidative stress-induced 
cell apoptosis in its targeting cells through suppression of BCL-XL.  In addition, 
BCL-XL and BCL-2 inhibitors would be another approach to enhance CML cell 
sensitivity to oxidative stress, especially in the cells with BCR-ABL-independent 
over-expression of BCL-2.  In this study, ABT737, the Bcl-2 homology domain 3 
(BH3) mimetic, was used as the pan-BCL-2/BCL-XL inhibitor.  ABT737 is the 
predecessor of Navitoclax (ABT263) using as a single agent against 
lymphoblastic leukemia in clinic trial.  ABT737 mediates the functional inhibition 
of BCL-XL and BCL-2 as antagonist with no suppression of their expression.   
BCR-ABL transformed cell line 32D-p210, derived from the murine 
myeloid cell 32D, was used to investigate the effects of Imatinib or ABT737 on 
oxidative stress induced apoptosis.  Imatinib was identified to induce a dramatic 
decrease of BCL-XL in 32D-p210 cells (Figure 47).  Pre-treatment of Imatinib or 
ABT737 enhanced H2O2-induced cell death in 32D-p210.  The percentage of 
viable cell was decreased from 89% to 34% or 65% in the combination of H2O2 
and Imatinib or ABT737 (Figure 48).   
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Figure 47. Imatinib induces BCL-XL decrease in BCR-ABL-transformed cells.  
32D-p210 cells were incubated with 0.25 µM Imatinib for 12 hours. 
The change of BCL-XL was identified by Western blotting using 
BCL-XL antibody.  Actin was used as a loading control. 
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Figure 48. Imatinib and ABT737 enhance oxidative stress-induced apoptosis 
in BCR-ABL-transformed cells.  32D-p210 cells were treated with 
50 µM H2O2 for 12 hours following the 12 hour pre-incubation of 
0.25 µM Imatinib or 2 µM ABT737. Cell apoptosis was detected by 
Annexin-V/PI assay.  Percentages of survival cells are labeled. 
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Based on the results from 32D-p210 study, the effects of Imatinib and 
ABT737 on oxidative stress-induced apoptosis were further tested in K562 cells.  
Because K562 cells have relative high BCL-XL expression but low BCL-2 
expression.  The results from K562 would be more representing the effects of 
suppression or inhibition of BCL-XL in CML cells. Consistent with the 32D-p210 
results, Imatinb caused a decrease of BCL-XL in K562 (Figure 49).  Pre-
treatment of Imatinib or ABT737 enhanced H2O2 induced cell death in K562.  The 
percentage of viable cell was decreased from 87% to 25% or 79% to 47% in the 
combination of H2O2 and Imatinib or ABT737, respectively (Figure 50, Figure 51).  
Since the previous observation showed BCL-XL prevents oxidative stress 
induced mitochondrial membrane potential collapse (Figure 23), the change of 
mitochondrial membrane potential was further measured in the combination of 
H2O2 and Imatinib or ABT737.  Pre-treatment of Imatinib or ABT737 sensitized 
K562 cells to H2O2 induced mitochondrial membrane potential collapse.  The 
percentage of cells with collapsed mitochondrial membrane potential was 
increased from 5% to 37% or 11% to 33% by the combination of H2O2 and 
Imatinib or ABT737, respectively (Figure 52, Figure 53).  Because BCL-XL is 
heavily localized to mitochondria, the change of mitochondria-bound BCL-XL was 
investigated in the isolated mitochondria fragments.  A large decrease of 
mitochondria-bound BCL-XL was observed in the cells pre-treated with Imatinib 
or ABT737 (Figure 54).  This data indicated that Imatinib and ABT737 enhance 
oxidative stress-induced cell damage through decrease the amount of 
mitochondrial BCL-XL.  
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Figure 49. Imatinib induces BCL-XL decrease in K562 cells.  K562 cells were 
incubated with 1 µM Imatinib for 12 hours. The change of BCL-XL 
was identified by Western blotting using BCL-XL antibody.  Actin 
was used as a loading control. 
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Figure 50. Imatinib enhances oxidative stress-induced apoptosis in K562 cells.  
K562 cells were treated with 50 µM H2O2 for 24 hours following the 
12 hour pre-incubation of 1 µM Imatinib. Cell apoptosis was 
detected by Annexin-V/PI assay.  Percentages of survival cells are 
labeled. 
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Figure 51. ABT737 enhances oxidative stress-induced apoptosis in K562 
cells.  K562 cells were treated with 50 µM H2O2 for 24 hours 
following the 12 hour pre-incubation of 2 µM ABT737. Cell 
apoptosis was detected by Annexin-V/PI assay.  Percentages of 
survival cells are labeled. 
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Figure 52. Imatinib sensitizes K562 cells to oxidative stress-induced 
mitochondrial membrane potential collapse.  K562 cells were 
treated with 50 µM H2O2 for 12 hours following the 12 hour pre-
incubation of 1 µM Imatinib. Changes of Mitochondrial membrane 
potential were measured by Rhodamine 123 staining assay.  
Percentages of the mitochondrial membrane collapsed cells are 
labeled. 
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Figure 53. ABT737 sensitizes K562 cells to oxidative stress-induced 
mitochondrial membrane potential collapse.  K562 cells were 
treated with 50 µM H2O2 for 12 hours following the 12 hour pre-
incubation of 2 µM ABT737. Changes of Mitochondrial membrane 
potential were measured by Rhodamine 123 staining assay.  
Percentages of the mitochondrial membrane collapsed cells are 
labeled. 
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Figure 54. Imatinib and ABT737 cause mitochondrial BCL-XL decrease in 
K562 cells.  K562 cells were treated or non-treated with 50 µM 
H2O2 for 6 hours following the 12 hour pre-incubation of 1 µM 
Imatinib or 2 µM ABT737. Mitochondria fragments were isolated.  
BCL-XL was identified by Western blotting using BCL-XL antibody.  
BAX, HSP60 and ATP synthase subunit-α were used as the 
internal controls. 
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4.4.3 Combination of PEITC with Imatinib or ABT737 Promotes Potent Cell 
Killing Effects in CML Cells.    
PEITC can induce intrinsic oxidative stress and promote massive cell 
death in CML cells; however, the major concern of PEITC is its non-specific 
oxidative stress effects on normal cells.  A proper drug combination to decrease 
the minimum effective dose of  PEITC will limit its side effects and enhance its 
therapeutic selectivity.  The designs of Imatinib and ABT737 were derived from 
the concept of targeted therapy. Imatinib and ABT737 specifically suppress their 
cellular targeting molecules and only disrupt their targeting cells.  Therefore, the 
combination of targeted therapeutic agents with PEITC would only drive the 
targeted cells hyposensitive to oxidative stress.  Ideally, the lower minimum 
effective dose of PEITC and the higher selectivity could be achieved.   
PEITC dramatically promoted ROS generation in CML cell lines K562 and 
KBM5 (Figure 55).  PEITC was used in this experiment at dose of 5 µM, which 
has no growth inhibition effect on normal peripheral blood mononuclear cells 
(Figure 33).  Pre-treatment of Imatinib sensitized K562 cells to PEITC induced 
mitochondrial membrane potential collapse.  The percentage of cells with 
collapsed mitochondrial membrane potential was increased from 11% to 35% in 
the combination of PEITC and Imatinib (Figure 56).  Consistently, pre-treatment 
of Imatinib enhanced PEITC induced cell death in K562.  The percentage of 
viable cell was decreased from 70% to 36% in the combination of PEITC and 
Imatinib (Figure 57).  These results indicated that combination of Imatinib and 
PEITC is very potent to promote cell killing effects in CML cells.  In addition, pre-
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treatment ABT737 also enhanced PEITC induced cell death in K562.  The 
percentage of viable cell was decreased from 67% to 30% in the combination of 
PEITC and ABT737 (Figure 58).  Because KBM5 cells showed relatively higher 
expression of BCL-2, which may delay cell death (Figure 20), inhibition of BCL-2 
and BCL-XL by ABT737 would enhance or accelerate oxidative stress-induced 
apoptosis in KBM5.  As expected, pre-treatment of ABT737 enhanced PEITC-
induced cell death in KBM5.    The percentage of viable cell was decreased from 
63% to 42% in the combination of PEITC and ABT737 (Figure 59).    
Based on the above results, the combination of redox modulation with 
suppression of BCL-2 family survival factor function would be an effective 
strategy to eliminate CML cells.  Especially, the combination of PEITC with 
Imatinib or ABT737 is worthy of further pre-clinical and clinical investigation.  
Additionally, my study also suggested that the targeted therapy agents could be 
used as the specific sensitizers to decrease the tolerance of malignant cells to a 
certain stress.   
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Figure 55. PEITC promotes cellular ROS generation in CML cells.  K562 and 
KBM5 cells were treated with 10 µM PEITC for 2 hours.  Cellular 
ROS contents were measured by flow cytometric using CM-H2DCF-
DA fluorescence dye.  Medians are labeled. 
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Figure 56. Imatinib sensitizes K562 cells to PEITC-induced mitochondrial 
membrane potential collapse.  K562 cells were treated with 5 µM 
PEITC for 12 hours following the 12 hour pre-incubation of 1 µM 
Imatinib. Changes of Mitochondrial membrane potential were 
measured by Rhodamine 123 staining assay.  Percentages of the 
mitochondrial membrane collapsed cells are labeled. 
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Figure 57. Imatinib enhances PEITC-induced apoptosis in K562 cells.  K562 
cells were treated with 5 µM PEITC for 24 hours following the 12 
hour pre-incubation of 1 µM Imatinib. Cell apoptosis was detected 
by Annexin-V/PI assay.  Percentages of survival cells are labeled. 
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Figure 58. ABT737 enhances PEITC-induced apoptosis in K562 cells.  K562 
cells were treated with 5 µM PEITC for 24 hours following the 12 
hour pre-incubation of 2 µM ABT737. Cell apoptosis was detected 
by Annexin-V/PI assay.  Percentages of survival cells are labeled. 
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Figure 59. ABT737 enhances PEITC-induced apoptosis in KBM5 cells.  KBM5 
cells were treated with 5 µM PEITC for 24 hours following the 12 
hour pre-incubation of 2 µM ABT737. Cell apoptosis was detected 
by Annexin-V/PI assay.  Percentages of survival cells are labeled. 
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5. Discussion 
5.1 BCR-ABL-Induced Cellular Oxidative Stress. 
An increase of ROS has been observed in human CML primary cells by 
comparing with the bone marrow cells isolated from healthy donors. 58,59,61 ROS 
is believed to mediate multiple biological alterations involved in CML 
development. 63  Consistent with previous studies, I have also identified that 
higher ROS levels present in BCR-ABL over-expressing cells. 58-60  Additionally, 
my study emphasized the supplement of glucose in cell culture is essential to 
mediate BCR-ABL-induced the increase of cellular and mitochondrial ROS.  
These results suggested that patient’s glucose nutrition conditions and the blood 
glucose levels should be considered for CML disease management, especially 
for CML prevention purpose.  Since the activation of mitochondria by glucose 
metabolism is a process involved multiple enzymes involving in glycolysis, 
pyruvate consumption and TCA cycle, the related genetic alterations of these 
enzymes may be detectable.  I compared the expressions of metabolic enzymes 
between K562 and normal bone marrow CD34+ cells, based on the profile from 
NCBI GEO database.  In GEO profile GDS596, most enzymes of glycolysis and 
TCA cycle are more expressed in K562 cells than normal bone marrow CD34+ 
cells (Figure 60, Figure 61). In addition, pyruvate carboxylase, the enzyme 
catalyzing irreversible carboxylation of pyruvate to form the critical TCA cycle 
intermediate oxaloacetate, is also more expressed in K562 (Figure 62).  This 
analysis provided the hint of using metabolic enzymes as the biomarker to 
evaluate the development of CML.  
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Figure 60. Expression profiles of glycolytic enzymes in K562 cells.  GDS596 
data profile was downloaded from Gene Expression Omnibus 
(GEO) (NCBI).  The expressions of glycolysis pathway enzymes in 
K562 cells (GSM18897 and GSM18898) were analyzed.  CD34+ 
bone marrow cells (GSM18885 and GSM18886) were used as 
controls.  The fold changes of gene expression were listed with 
gene name and probe codes.  Red indicates increase, and green 
indicates decrease. 
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Figure 61. Expression profiles of TCA cycle enzymes in K562 cells.  GDS596 
data profile was downloaded from Gene Expression Omnibus 
(GEO) (NCBI).  The expressions of TCA cycle enzymes in K562 
cells (GSM18897 and GSM18898) were analyzed. CD34+ bone 
marrow cells (GSM18885 and GSM18886) were used as controls.  
The fold changes of gene expression were listed with gene name 
and probe codes.  Red indicates increase, and green indicates 
decrease. 
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Figure 62. Expression profiles of Pyruvate carboxylase (PC), pyruvate 
dehydrogenases (PDHA1 and PDHB) and lactate dehydrogenases 
(LDHA and LDHB) in K562 cells.  GDS596 data profile was 
downloaded from Gene Expression Omnibus (GEO) (NCBI).  
Pyruvate carboxylase (PC), pyruvate dehydrogenases (PDHA1 and 
PDHB) and lactate dehydrogenases (LDHA and LDHB) 
expressions of K562 cells (GSM18897 and GSM18898) were 
analyzed. CD34+ bone marrow cells (GSM18885 and GSM18886) 
were used as control.  The fold changes of gene expression were 
listed with gene name and probe codes.  Red indicates increase, 
and green indicates decrease. 
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5.2 Differential Roles of BCL-XL and BCL-2 in Protecting Mitochondria 
Under Oxidative Stress. 
BCL-XL and BCL-2 play important roles in negatively regulating 
mitochondria dependent apoptosis through inhibiting Apaf-1 mediated Caspase-9 
activation. 131-133 BCL-2 family survival factors maintain mitochondrial integrity by 
preventing cytochrome c release. 134 However, there is no clear evidence to 
demonstrate the distinct roles of BCL-XL and BCL-2 in response to different 
apoptosis stimuli.  Therefore, one goal of my study was to investigate the 
efficiency of BCL-XL and BCL-2 in preventing oxidative stress induced cell 
damage in CML.  According to my results, BCL-XL actually is more essential 
than BCL-2 to protect mitochondria against oxidative stress in CML cells.   It is 
worthy of noting that unlike BCL-XL, the higher expression of BCL-2 has been 
mainly observed in blast crisis patients but not chronic phase CML patients. 
135,136
 These studies have suggested that BCL-2 is most likely functional as the 
secondary survival factor during the development of malignancy in CML.  In 
addition, CML malignancy is driven by the myeloid progenitors.  The promotion of 
cell proliferation in the early stage progenitors is often linked with ROS increase 
and differentiation. 137,138 Intriguingly, one recent study has shown that the 
expression of BCL-XL and BCL-2 is completely opposite during the differentiation 
of human bone marrow mesenchymal stem cells. 139 In this study, researchers 
have identified that the expression of BCL-XL is at the similar level in 
undifferentiated and differentiated cells, however, BCL-2 only expresses in 
differentiated cells.  Additionally, they have demonstrated that BCL-XL but not 
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BCL-2 plays the dominant survival role in undifferentiated cells.  So the 
differential roles of BCL-XL and BCL-2 in response to oxidative stress in CML 
cells may involve a cell stage impact.   
Previous studies have shown that BCL-XL and BCL-2 also regulate 
cellular redox capacity.  BCL-XL regulates mitochondrial membrane potential and 
protects oxidative stress-caused GSH pool decrease. 69,70 BCL-2 incorporates 
with antioxidants and regulates cellular GSH distribution. 140,141  Surprisingly, 
BCL-2 has also been viewed as a pro-oxidant to promote mitochondrial ROS 
generation. 142 To address such a controversy, the effects of BCL-XL and BCL-2 
on BCR-ABL promoted mitochondrial ROS generation were investigated.  The 
mitochondrial ROS levels of BCL-XL or BCL-2 over-expressing K562 cells were 
detected with or without glucose in culture media.  The 5 hour shortage of 
glucose caused a decrease of mitochondrial ROS in both BCL-XL over-
expressing cells and parental cells, but not in BCL-2 over-expressing cells 
(Figure 63).  The similar phenomenon also observed through the comparison 
between K562 and KBM5.  KBM5 cells, with relatively high BCL-2 expression, 
were less sensitive to 5 hour glucose shortage-induced mitochondrial ROS drop 
than K562 (Figure 64).  These results suggested that BCL-2 seems play a role in 
maintaining mitochondrial ROS generation in CML, and implied a disadvantage 
of BCL-2 in protecting mitochondria under oxidative stress. 
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Figure 63. BCL-2 over-expressing cells are less sensitive to short term 
glucose shortage-induced mitochondrial ROS decrease.  
Mitochondrial ROS levels were detected by MitoSOX Red.  K562, 
K562-BCLXL-HA and K562-BCL2-GFP cells were cultured in 
regular or glucose free media for 5 hours.  
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Figure 64. BCL-2 high cells are less sensitive to short term glucose shortage-
induced mitochondrial ROS decrease.  Mitochondrial ROS levels 
were detected by MitoSOX Red.  K562 and KBM5 cells were 
cultured in regular or glucose free media for 5 hours.  The medians 
are labeled. 
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5.3 Role of Intracellular GSH Pool for Survival. 
My results indicated that the depletion of cellular glutathione appeared to 
be an important biochemical event mediating the cytotoxic effects of PEITC.  
GSH is viewed as a critical survival antioxidant.  A previous study has identified 
that the levels of GSH determine cell sensitivity to apoptosis in leukemia cells. 143 
Consistently, a severe depletion of GSH before cell apoptosis was found in my 
experiments (Figure 29, Figure 30B).  Intriguingly, my colleague has identified 
that PEITC results in a rapid depletion of mitochondrial GSH and disruption of 
mitochondrial metabolism function before inducing an entire cellular GSH pool 
loss in leukemia cells. 144 These results suggested that the non-mitochondria 
GSH seemed to function as the barrier to prevent the activation of the 
downstream steps in apoptosis.  Since caspase-3 activation and PARP cleavage 
matched the decrease of total GSH in my experiments (Figure 34, Figure 29), I 
did an in vitro test to evaluate the effects of GSH levels on caspase-3 mediated 
PARP cleavage.  I observed that 3 mM GSH prevented the spontaneous PARP 
cleavage in CML cell lysates (Figure 65).  I further found that 3 mM GSH also 
inhibited caspase-3 mediated PARP cleavage in cell lysates (Figure 66).  These 
results suggested that GSH may play a role in the direct regulation of apoptotic 
activation.  The potency of PEITC in inducing cell death may be also due to 
enhancing cell apoptotic sensitivity by depleting GSH. 
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Figure 65. GSH prevents spontaneous PARP cleavage in vitro.  KBM5 cell 
pellets were collected.  Cell lysate samples were transferred into 
100 µl aliquots.  The aliquots were incubated in the presence or 
absence of 3 mM GSH at 37 °C for 3, 10 or 60 minutes, and then 
collected for Western blotting to detect PARP cleavage.  The GSH 
incubation-caused precipitated proteins were also collected and 
blotted with PARP antibody to exclude the precipitation-caused 
decrease of cleaved PARP. 
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Figure 66. GSH prevents caspase-3 induced PARP cleavage in vitro.  KBM5 
cell pellets were collected.  Cell lysate samples were transferred 
into 100 µl aliquots.  The aliquots were incubated in the presence or 
absence of active caspase-3 enzymes or 3 mM GSH at 37 °C for 
60 minutes, and then collected for Western blotting to detect PARP 
cleavage.   
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5.4 Potential Advantage of PEITC in Redox-Directed Therapy in CML. 
‘The increase of ROS stress in CML cells expressing either wild-type or 
mutant BCR-ABL can be exploited for therapeutic purpose.  Recently, the redox-
directed therapeutic strategy has drawn researchers’ attention. 145 My present 
study has suggested that the severe ROS stress induced by PEITC might alter 
the redox state of BCR-ABL proteins, including the T315I mutant, and render it 
vulnerable to degradation by caspase-3.  This notion is supported by the 
observation that either NAC or specific inhibitor of caspase-3 could significantly 
suppress the cleavage of BCR-ABL.  It should be pointed out that the 
degradation of BCR-ABL may not be the primary cause of PEITC-induced cell 
death, which is likely triggered by direct oxidative damage to mitochondria and 
other critical cellular molecules.  However, the ability of PEITC to induced rapid 
degradation BCR-ABL may effectively abolish the pro-survival signal of this 
oncoprotein, thus add to the potency of this compound in killing CML cells.  
Furthermore, normal lymphocytes have a lower basal ROS output and possess 
intact redox-regulatory machinery, which make them less vulnerable to ROS 
stress imposed by PEITC.  Based on the promising activity of PEITC against 
Imatinib-resistant CML cells, its therapeutic selectivity, and its unique mechanism 
of action, I conclude that this compound may be useful to overcome CML 
resistance to kinase inhibitors.’114  
5.5 Potential Advantage of Imatinib in Redox-Directed Therapy in CML. 
One of the major concerns of redox-directed therapeutics is the off-
targeting effects on the normal cells. Therefore, the improvement of the 
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therapeutic selectivity would make this strategy more beneficial.  Oncoprotein 
BCR-ABL, encoded by CML specific Bcr-Abl fusion gene, has been identified in 
more than 95% CML cases. 45-47  In the past few years, molecular targeting BCR-
ABL functional inhibitors were derived from the concept of targeted therapy and 
developed for the chemotherapy of CML. 90 Imatinib specifically suppresses its 
cellular targeting molecules and only disrupts the targeted cells.  The 
combination of Imatinb with redox modulation agents would only drive the 
Imatinib targeting cells hyposensitive to oxidative stress.  Therefore, the lower 
minimum effective dose of redox modulation agents and the higher therapeutic 
selectivity could be achieved.  
5.6 Antioxidant Defects in CML. 
My results suggested that anti-apoptotic factors play essential roles in 
preventing oxidative stress-induced cell damage in BCR-ABL expressing cells.   
However, there are other genes, antioxidant enzymes, constantly scavenging 
ROS in normal physiological conditions.  Why do CML cells highly rely on the 
anti-apoptotic factors? Are the antioxidant enzymes deregulated in CML cells?  
These are the questions left for future studies. 
One of the major antioxidant enzymes, GPX1, has been reported to 
dysfunction or lost in some BCR-ABL positive patients or cultured human CML 
cell lines. 92,108  However, no study has yet demonstrated the link between the 
regulation of GPX1 and the induction of BCR-ABL. GPX1 is the selenium (Se)-
dependent antioxidant enzyme, mainly catalyzing the reduction of the cytosolic 
H2O2 using GSH as the substrates.  The regulation of cellular GPX1 expression 
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is through multiple optional signaling pathways and largely remains unknown. 
The binding sequences of PU.1 and p53 have been identified in GPX1 promoter 
region. 146,147 It is worth noting that p53 has been reported to be mutated or 
deleted in many CML cases. 148 In addition, a previous study suggested that 
FOXO3a also plays an important role in regulating GPX1 gene expression. 149  
Furthermore, the inhibition of FOXO3a activity has been observed in v-Abl 
transformed cells.150  These studies suggest that BCR-ABL might interrupt the 
expression of GPX1 through inhibiting its upstream transcription factors.  BCR-
ABL-transformed cell 32D-p210 showed increased phosphorylation at FOXO3a 
Thr32, which inhibits FOXO3a activation (Figure 67A).   In addition, a decreased 
gene expression of GPX1 was also observed in 32d-P210 (Figure 67A, B, 
P=0.0017).  These data implied that over-expression of oncogene BCR-ABL may 
cause some crucial antioxidant defects and render the transformed cells more 
dependent on anti-apoptotic factors to respond oxidative stress.   
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Figure 67. Over-expression of BCR-ABL results in FOXO3a inhibition and 
GPX1 decrease.  (A) Phosphorylation of FOXO3a Thr32 and GPX1 
were detected in samples from 32D-p210 and 32D parental by 
Western blotting.  (B) GPX1 mRNA expression was measured by 
quantitative real-time PCR as described in previous Materials and 
Methods 3.13. 
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6. Summary and Conclusion 
In conclusion, the present studies have demonstrated that BCR-ABL 
promotes cellular and mitochondrial ROS generation, while elevating the cell 
survival factors GSH and BCL-XL to prevent oxidative stress-induced apoptosis.  
Enhancement of glucose metabolism by BCR-ABL contributes to the increase of 
mitochondrial ROS in CML cells.  These findings have provided insight into the 
persistent oxidative stress observed in CML cells.  In addition, the current 
research has identified the distinct roles of BCL-XL and BCL-2 in preventing 
excessive ROS induced apoptosis, which are due to their differential function in 
protecting mitochondria against oxidative stress.  Based on the biological 
mechanism studies, novel therapeutic strategies were investigated.  PEITC 
effectively promotes massive cell death in Imatinib-resistant CML cells through 
targeting cellular GSH system.  The combination of either Imatinib or ABT737 
with PEITC diminishes the protecting effects of BCL-2 family survival factors and 
promotes excessive intrinsic oxidative stress; thus showing  cell killing effects in 
CML cells.  This therapeutic strategy could ultimately improve the selectivity and 
potency of redox-directed therapy in CML and other hematological malignancies 
(Figure 68). 
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Figure 68. Model summarizing the biological basis and clinical implications of 
BCR-ABL-induced mitochondrial oxidative stress and cell survival.  
Tyrosine kinase onco-protein BCR-ABL promotes mitochondrial 
ROS increase through the enhancement of glycolysis.  BCR-ABL 
down-stream survival factor BCL-XL plays an essential role in 
preventing oxidative stress-caused mitochondria damage and cell 
apoptosis.  Redox modulating reagent PEITC induces potent cell 
death in CML cells by depleting GSH and promoting intrinsic 
oxidative stress.  Combination of PEITC with BCR-ABL inhibitor 
Imatinib or BCL-XL/BCL-2 inhibitor ABT737 strengthens redox 
modulation-induced cell death in CML.  Glut: Glucose transporter; 
HK: Hexokinase; LDH: Lactate dehydrogenase; P: phosphorylation; 
TCA: TCA cycle; I,II,III and IV: Mitochondrial respiratory chain 
complex I to IV; C: Cytochrome c.  
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